

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Etiology of ear infection and antimicrobial susceptibility pattern among patients attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-068359
Article Type:	Original research
Date Submitted by the Author:	15-Sep-2022
Complete List of Authors:	Shangali, Aminiel; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology; Mwanza University, Department of Microbiology and Immunology Kamori, Doreen; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Massawe, Willybroad; Muhimbili National Hospital, Department of Otorhinolaryngology Masoud, Salim; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Kibwana, Upendo; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Mwingwa, Anthony G.; Kilimanjaro Christian Medical Centre, Department of Microbiology and Immunology Manisha, Anselmo; Mwanza University, Department of Microbiology and Immunology Mwandigha, Ambele M.; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Mirambo, Mariam M; Catholic University of Health and Allied Sciences, Department of Microbiology and Immunology Mshana, Stephen E.; Catholic University of Health and Allied Sciences, Department of Microbiology and Immunology Manyahi, Joel; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Majigo, Mtebe; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology
Keywords:	Microbiology < PATHOLOGY, MYCOLOGY, BACTERIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Etiology of ear infection and antimicrobial susceptibility pattern among patients**
4 **attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania**
5
6
7
8
9

10
11 **Authors**
12

13 Aminiel Shangali^{1,3}, Doreen Kamori^{1,*}, Willybroad Massawe², Salim Masoud¹, Upendo O.
14 Kibwana¹, Anthony G. Mwingwa¹, Anselmo Manisha³, Ambele M. Mwandigha¹, Mariam
15 Mirambo⁴, Stephen E. Mshana⁴, Joel Manyahi¹, Mtebe V. Majigo¹
16
17
18
19

20
21 **Affiliation**
22

23
24 ¹ Department of Microbiology and Immunology, Muhimbili University of Health and Allied
25 Sciences, Dar es Salaam, Tanzania; ² Department of Otorhinolaryngology, Muhimbili
26 National Hospital, Dar es Salaam, Tanzania; ³ Department of Microbiology and Immunology,
27 Mwanza University, Mwanza, Tanzania; ⁴ Department of Microbiology and Immunology,
28 Catholic University of Health and Allied Sciences, Mwanza, Tanzania
29
30
31
32
33
34

35
36 **Email addresses.**
37

38 AS: arshangali@gmail.com AM: anselmomanisha@gmail.com
39 DK: doreenkamori@gmail.com AMM: ambelemawazo@gmail.com
40 WM: dwmassay@gmail.com MM: mmmirambo@gmail.com
41 SM: salimsmasoud@gmail.com SEM: stephen72mshana@gmail.com
42 UOK: pendokibwana@gmail.com JM: manyahijoel@yahoo.com
43 AGM: anthonymwingwa@gmail.com MVM: mmajigo@gmail.com
44
45
46
47
48

49 ***Correspondence:**
50

51 Doreen Kamori (MD, Ph.D.)
52 Muhimbili University of Health and Allied Sciences, P.O Box 65001, Dar es Salaam,
53 Tanzania, Phone number: +255 711 954 661, Email: doreenkamori@gmail.com
54
55
56
57 ORCID ID: <http://orcid.org/0000-0001-5162-6554>
58
59
60

1
2
3 **Keywords:** Ear infection, resistance, antimicrobial susceptibility pattern.
4

5 **ABSTRACT**
6

7
8 **OBJECTIVES:** To determine the etiological pathogens causing ear infections and their
9 antimicrobial susceptibility patterns among patients with ear complaints at a tertiary hospital
10 in Dar es Salaam.
11
12
13
14

15
16 **DESIGN:** Hospital-based cross-sectional study.
17

18
19 **SETTINGS:** Otorhinolaryngology clinic at Muhimbili National Hospital, Dar es Salaam,
20 Tanzania.
21
22

23
24 **PARTICIPANTS:** Patients presenting with signs and symptoms of ear infection.
25

26
27 **MAIN OUTCOME MEASURE:** Bacteria and fungi isolated from ear swab specimens of
28 patients presenting with signs and symptoms of ear infection; and antimicrobial
29 susceptibility patterns of isolated bacteria.
30
31
32

33
34
35 **RESULTS:** Two hundred fifty-five participants were enrolled, with a median age of 31 years
36 and an interquartile range of 15- 49. Otitis externa was the predominant type of ear infection,
37 accounting for 45.1%. We observed positive bacteria culture in 53.3% of study participants,
38 where *S. aureus* (27.3%) and *P. aeruginosa* (24.2%) were the most frequently isolated
39 bacteria, while *Candida* spp, 12(63.8%), and *Aspergillus* spp, 9(36.2%) were the only isolated
40 fungi. We report that 93% of isolated *Enterobacteriales* were resistant to amoxicillin
41 /clavulanic acid, and 73% were resistant to ceftazidime. In addition, we detected 34.4%
42 extended-spectrum beta-lactamase-producing *Enterobacteriales* (ESBL-PE) and 44.4%
43 methicillin-resistance *Staphylococcus aureus* (MRSA).
44
45
46
47
48
49
50
51
52
53

54
55
56 **CONCLUSIONS:** The findings from this study reveal that the leading etiological agent of
57 ear infection is bacteria. Furthermore, our findings show a significant proportion of ESBL-PE
58
59
60

1
2
3 and MRSA-causing ear infections. Hence, detecting multidrug-resistant bacteria is crucial to
4
5 improving ear infection management.
6
7

8 **Strength and Limitation of the study**

9
10 The present reports of the common bacterial and fungi etiology of ear infection; importantly
11
12 the study has revealed the antimicrobial susceptibility patterns that is useful in guiding on the
13
14 choice of empirical treatment in resource limited settings.
15
16

17
18 The present has some limitations, some fungal (moulds) isolates were not identified at specie
19
20 level and anaerobic culture was not performed.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

An ear infection is among the leading cause of deafness in many developing countries. Unfortunately, most patients with ear infections in resource-limited settings delay seeking medical attention; hence, usually present with complications (1). Bacteria are the leading pathogens of ear infection whereby, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, and *Klebsiella species* are the dominant bacteria species causing ear infection globally (1–6). In addition, *Candida spp* and *Aspergillus spp* are predominant fungal isolates responsible for ear infections (7–10). However, fungal ear infections are often undiagnosed due to limited diagnostic opportunities, especially in resource-limited countries, including Tanzania (5,6).

Most practitioners in our settings tend to treat ear infections empirically or adhere to the Standard Treatment Guideline (STG) without considering laboratory investigation and AST results. This has created a gap in managing most ear infections, which raises the risk of acquiring multidrug-resistant bacteria (11,12). When first-line antibiotics cannot treat infections, more costly antibiotics must be utilized. This consequently affects patients' treatment options, resulting in prolonged hospital stays and increased healthcare costs, which impacts families' financial burden and quality of life (13).

Etiological studies of ear infections are important to guide the choice of an effective antibiotic and monitoring bacterial patterns and their varying antimicrobial susceptibilities. This is crucial for risk analysis, mitigation measures, and logistical plans. Therefore, the present study aimed to determine the etiological pathogens and antimicrobial susceptibility patterns of bacteria causing ear infections. The data obtained will be used to strengthen the prevention and control measures and to update the management and treatment options for ear infections. Also, the information will serve as a baseline for countrywide surveillance of antibiotic resistance.

2. Materials and Methods

Study design and settings

We conducted a hospital-based cross-sectional study from March to July 2021 in the otorhinolaryngology clinic at MNH, Dar es Salaam, Tanzania. The hospital serves as a National Referral Hospital, research center, and a university teaching hospital. MNH is the largest tertiary health care facility in Tanzania. The otorhinolaryngology department has inpatient and outpatient units; about 20 to 30 patients attend the outpatient clinic per day.

Study participants

The study included patients attending the otorhinolaryngology clinic with signs and symptoms of ear infection such as accumulation of fluid in the middle ear, bulging of the eardrum, ear pain, ear itching, perforation of the eardrum, and ear discharge (otorrhea). We excluded patients with other hearing disorders unrelated to infection (congenital malformations, physical head injury) and those on regular checkups.

Sample size, and sampling procedure

The study sample size was estimated using a Kish Leslie formula (1965) for a cross-sectional study considering the prevalence of 62.1% reported previously by Moshi et al in a study conducted in a tertiary hospital in Mwanza city, Tanzania (3). The minimum sample size was 241 participants; considering the 5% non-response rate, we obtained a sample size of 255 participants.

Data collection

Data collection was conducted by two trained research assistants (RAs) and an ear, nose, and throat (ENT) surgeon; briefly, a structured questionnaire was administered to the participants by two RAs. RAs used the questionnaire to collect demographic data (age, sex, marital status,

1
2
3 occupation, and education) and behavioral risk characteristics (swimming, frequent use of
4 earphones, cotton buds, sharp objects, and cigarette smoking). In addition, the participants'
5 clinical information, including the type of ear infection, use of antibiotics, nasal congestion or
6 blockage, recurrent upper respiratory tract infection (URTI), and cerumen impaction, were
7 also collected from the patient's medical records and during a physical examination by ENT
8 surgeon.
9
10
11
12
13
14
15
16
17

18 **Specimen collection**

19
20 The ENT surgeon collected specimens with precaution to prevent contamination. The sterile
21 swab was used to clear the oozing pus from the patient's ear; another sterile swab was then
22 used to extract fresh pus from the ear. The collected specimen was stored at room
23 temperature in Stuart transport media. All samples were transported to the Central Pathology
24 Laboratory (CPL) at MNH for processing and testing.
25
26
27
28
29
30
31
32

33 **Isolation and identification**

34
35 Upon the arrival of the specimens at CPL, specimens were processed for culture and
36 identification. Specimens were inoculated on selective and non-selective media; Chocolate
37 agar (CA), Sheep-Blood agar (sBA), MacConkey agar (MCA), and Sabouraud dextrose agar
38 (SDA). We used CA to isolate fastidious bacteria, such as *H. influenza* and *S. pneumoniae*,
39 the frequent etiological agents of ear infection. MCA was used as a selective and differential
40 medium for Gram-negative bacteria, and BA was used as a general-purpose medium. SDA
41 was used for the isolation of fungal species. We incubated MCA in an aerobic environment
42 and BA and CA in a 5% CO₂ environment at 37°C for 18 to 24 hours.
43
44
45
46
47
48
49
50
51
52
53

54
55 Bacterial isolates were identified by interpreting colonial morphologies, microscopic
56 examination (Gram stain), and biochemical tests. The catalase and coagulase tests were
57 performed for Gram-positive bacteria, while Kligler's Iron Agar, Sulfur Indole Motility
58
59
60

1
2
3 (SIM), citrate, and urease tests were for gram-negative bacteria. Further, phenotypical
4
5 identification and confirmation of Gram-negative bacterial isolates were performed by
6
7 Analytical Profile Index tests, API 20E and API 20NE.
8
9

10
11 For fungal isolates, growth on the SDA plate was used preliminary to classify mold or yeast
12
13 based on the colonial morphology and color. A germ tube test was used to identify *Candida*
14
15 *albicans*. Additionally, Lactophenol cotton blue was used for molds to identify the conidial
16
17 spore in *Aspergillus spp.*
18
19

20 21 **Antimicrobial susceptibility testing**

22
23 Antibiotic susceptibility test (AST) for bacterial isolates was performed using the Kirby
24
25 Bauer disc diffusion method on Mueller-Hinton Agar (MHA), and MHA supplemented with
26
27 5% blood for *S. pneumonia* following the 2021 Clinical and Laboratory Standard Institute
28
29 (CLSI) guidelines. Zones of inhibition were measured using a ruler in millimeters and
30
31 interpreted as susceptible, resistant, or intermediate according to the 2021 CLSI guideline.
32
33

34
35 The antibiotic discs used were; ciprofloxacin (5µg), trimethoprim/ sulphamethoxazole
36
37 (1.25/23.75µg), gentamycin (10µg), clindamycin (2 µg), erythromycin (15µg,) for gram-
38
39 positive bacteria. Ciprofloxacin (5µg), trimethoprim/ sulphamethoxazole (1.25/23.75µg),
40
41 gentamycin (10µg), meropenem (10µg), amoxicillin/ clavulanic acid (20µg), ceftriaxone
42
43 (30µg) and ceftazidime (30µg) for *enterobacteriaceae* and *Acinetobacter spp.* Ciprofloxacin
44
45 (5µg), gentamycin (10µg), meropenem (10µg) and ceftazidime (30µg) for *Pseudomonas spp.*
46
47
48
49
50

51
52 Standard methods were used to identify MRSA using ceftazidime (30µg) disc in which resistant
53
54 isolates were considered MRSA positive. In addition, ESBL-PE screening was done using
55
56 ceftazidime (30 µg) and cefotaxime (30µg) antibiotic discs, and if resistant, ESBL- PE
57
58 confirmation was done by the double-disc synergy method (14).
59
60

Quality control

The reference organisms and reagents were clearly and uniquely labeled, dated, and stored at optimal conditions. The room, incubator, and refrigerator temperature were monitored daily.

The culture media were prepared following the manufacturer's guidelines and internal standard operating procedures and tested for performance and sterility.

Data Analysis

The data was analyzed using SPSS version 23 software. Continuous variables were summarized as the median and interquartile range (IQR), whereas percentages and proportions were used to describe categorical variables. The percentage of resistance was obtained by computing the number of bacteria species that resisted a specific drug over a total number of isolated bacterial species. AST intermediate results were regarded as resistant.

Patient and public involvement

Patients and the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

3. Results

Participants' demographic, clinical, and risk behavior characteristics

Two hundred fifty-five participants were recruited; 52.5% (134/255) were males. The median age was 31 years (IQR: 15- 49). The majority (30.2%) of participants were students, 32.9% had a college education, and 15.7% were from outside Dar es Salaam region (Table 1). The median duration of ear infections was 210 days (IQR: 21-1095). Otitis externa (OE) was the most common type of ear infection, accounting for 45.1% (115/255), followed by Chronic Suppurative Otitis Media (CSOM) (41.2%) (Figure 1).

1
2
3 Around 49% of the participants with ear infections had a history of antibiotic use, whereby
4 ciprofloxacin ear drop was the most prescribed topical antibiotic. Additionally, 33.3% of the
5 study participants had nasal congestion/blockage/discharge, and 28.2% had recurrent URTI
6
7
8
9
10 (Table 2).

11 12 13 **Distribution of bacterial and fungal isolates causing ear infections**

14
15 In this study, 136 out of 255 (53.3%) participants had a positive aerobic culture for either
16 bacterial or fungal pathogen, whereby 10.3% (14/136) of participants had a polymicrobial
17 infection (mixed growth of either two different bacteria or bacterial and fungal infection). A
18 total of 150 isolates (bacteria and fungi) were identified, of which 87.3% (131/150) were
19 bacteria. Of the isolated bacteria, Gram-negative, 71.0% (93/131) were predominant.
20
21
22
23
24
25
26

27 The predominant bacterial isolates were *S. aureus*, 27.5% (36/131), followed by
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Pseudomonas aeruginosa, 24.4% (32/131) (Figure 2A). On the other hand, *Candida spp*
accounted for 63.2% (12/19) of the isolated fungi (data not shown). Further stratification of
isolated pathogens by type of ear infection showed that *S. aureus* 16/131 (12.2%) was the
most prevalent bacterium in OE patients, whereas *P. aeruginosa* 22/131 (16.8%)
predominated in CSOM patients (Figure 2B).

In the present study 34.4% (21/61) of the enterobacterales, excluding *Pseudomonas*
aeruginosa, were extended-spectrum beta-lactamase producing enterobacterales (ESBL-
PE); and *Klebsiella spp* was predominant, accounting for 33.3% (7/21) of the ESBL-PE
isolates (Figure 2C). On the other hand, 44.4% (16/36) of the *S. aureus* species were MRSA
(data not shown).

Antimicrobial susceptibility pattern of bacterial isolates

Almost all (93%) isolated *Enterobacterales* were resistant to amoxicillin/clavulanic acid, more so *E. coli* and *Acinetobacter spp* were 100% resistant. Also, 73% of isolated bacteria were resistant to ceftazidime, whereby *Pseudomonas aeruginosa* had the highest resistance rate of 75%. In addition, 43% of isolated bacteria were resistant to trimethoprim-sulfamethoxazole, whereby *E.coli* was leading with a 75% resistance rate. Resistance towards sulfamethoxazole-trimethoprim was higher among ESBL producers (57-100%) than non-ESBL producers (29-100%). At least 14% of the non-ESBL-PE bacteria were resistant to all the third-generation cephalosporins, and all non-ESBL-PE isolates were sensitive to meropenem. *S. aureus* had an 89% resistance rate to erythromycin. However, MRSA isolates were more resistant to sulfamethoxazole-trimethoprim (81%) and gentamicin (50%) than non-MRSA isolates 35% and 25% for sulfamethoxazole-trimethoprim and gentamicin, respectively. Most isolated bacteria had very low resistance rate against meropenem (4%) and ciprofloxacin (22%) (Table 3).

4. Discussion

Understanding the etiology of ear infections and resistance pattern is crucial in planning interventions and managing ear infections. The results indicate a substantial proportion of ear infections, with bacteria as the primary etiological agent. Most isolated bacteria were resistant to third-generation cephalosporins, sulfamethoxazole-trimethoprim, and amoxicillin/clavulanic acid. Gram-positive bacteria were highly resistant to erythromycin. The two antibiotics that worked the best were ciprofloxacin and meropenem. The results

1
2
3 imply the need to review ear infection management and the selection of an efficient
4
5 antibiotic.
6
7

8 The study found that many ear infections are of bacterial etiology. The finding is similar to
9
10 studies done in Tanzania by Kennedy M et al. (2019) in Morogoro (4), Zephania A et al.
11
12 (2019) in Dar es Salaam (15), Martha M et al. (2016) in Mwanza (3) and other studies in
13
14 Kenya and India (16,17). We observed that *S. aureus* and *Pseudomonas aeruginosa* are ear
15
16 infections' leading bacterial etiological agents, similar to previous studies in Tanzania,
17
18 Nigeria, Angola, Kenya, and India (3,17–19). In addition, the present study found *Candida*
19
20 *spp* and *Aspergillus spp* the fungal spp, causing ear infections consistent with previous
21
22 findings in Tanzania and elsewhere (Nigeria, Iran, Ethiopia, Egypt, India) (3–5,20–22).
23
24 Nonetheless, the contribution of fungi etiology in ear infections in the present study was
25
26 expected because many individuals had risk behaviors for fungal ear infections, including
27
28 excessive use of eardrops containing antibiotics, regular cleaning of ears, and swimming.
29
30 Antibiotic overuse promotes the growth of fungi, and the regular ear cleaning habit removes
31
32 cerumen and exposes ears to fungi colonization and, subsequently, infection (23,24).
33
34
35
36
37
38

39 The current study revealed a high proportion of MRSA (44.4%) and ESBL-PE (34.4%). In
40
41 addition, our study showed *Klebsiella spp* (33.3%) as the dominant ESBL-PE. The higher
42
43 proportion of MRSA and ESBL-PE coincide with studies done in Tanzania by Martha M et al
44
45 among patients with chronic suppurative otitis media infection and another study in India
46
47 (3,16). The greater inclination for self- and empirically prescribing antibiotics without
48
49 considering laboratory culture and sensitivity may explain the higher proportion of ESBL and
50
51 MRSA. The high incidence of ESBL and MRSA can also be explained by an increased
52
53 inclination for people to visit hospital facilities due to chronic ear infection, which raises the
54
55 danger of exposure to MDR bacteria. Additionally, the tendency to use inanimate objects to
56
57
58
59
60

1
2
3 remove earwax can be attributed to the increased proportion of ESBL and MRSA, as these
4
5 inanimate objects are often found in environments that may be contaminated with ESBL-
6
7 producing bacteria and/or MRSA (25).
8
9

10
11 Almost all isolated bacteria (93%) were resistant to amoxicillin/clavulanic acid. Nearly three-
12
13 quarters of gram-negative bacteria were resistant to ceftazidime, and about half were resistant
14
15 to trimethoprim-sulfamethoxazole. On the other hand, 89% of isolate gram-positive were
16
17 resistant to erythromycin. ESBL-PE and MRSA isolates were resistant to the most common
18
19 antimicrobial agents compared to non-MRSA and non-ESBL-PE. The resistance patterns
20
21 found in the current study are similar to those reported in other studies in Tanzania, Kenya,
22
23 Ethiopia, India, Egypt, and Romania (3,4,17,18,26–29). The frequent use of these antibiotics
24
25 to treat various bacterial infections in our setting and the likelihood that most bacterial
26
27 species have developed resistance to antimicrobial drugs over time may contribute to the
28
29 observed resistance pattern.
30
31
32

33
34 In the present study, most isolated bacteria were sensitive to meropenem and ciprofloxacin.
35
36 Ciprofloxacin is a drug of choice for ear infections as per standard treatment guidelines in our
37
38 setting. The fact that meropenem is infrequently used to treat ear infections may explain the
39
40 high sensitivity rate. Surprisingly, we observed that ciprofloxacin is still effective despite
41
42 being prescribed often in our setting for treating ear infections. There is no clinical rationale
43
44 as to why quinolones are still more effective in treating ear infections, but these results assure
45
46 that quinolones are still beneficial as first-line topical antibiotics for ear infections.
47
48
49
50

51 52 **5. CONCLUSION**

53
54 The results of this study indicate that bacteria are the most common cause of ear infections in
55
56 our context. Furthermore, we report that many multidrug-resistant bacteria (ESBL-PE and
57
58 MRSA) are implicated in causing ear infections. Therefore, antimicrobial susceptibility
59
60

1
2
3 testing is crucial to guide clinicians on the appropriate management of ear infections in our
4
5 setting.
6

7
8 **Acknowledgements:** The authors wishes to acknowledge the Muhimbili National Hospital
9
10 (MNH) administration and the Mwanza University, Tanzania for their support. The authors
11
12 are also grateful to all the study participants, the otorhinolaryngology clinic staff, and CPL
13
14 staff at MNH.
15

16
17
18 **Contributors:** AS, DK, and WM contributed to the conceptualization, data collection, and
19
20 analysis study . AS, DK, WM, UK, AGM, AM, SM, AMM, MM, SEM, JM, and MM were
21
22 involved in manuscript preparation. JM and MM profoundly reviewed the manuscript. AS is
23
24 guarantor of the study. The corresponding author attests that all listed authors meet
25
26 authorship criteria and that no others meeting the criteria have been omitted. The lead author
27
28 (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and
29
30 transparent account of the study being reported; that no important aspects of the study have
31
32 been omitted; and that any discrepancies from the study as planned (and, if relevant,
33
34 registered) have been explained
35
36
37
38
39

40 **Funding:** No funding was received for this study.
41

42
43 **Competing interests:** The authors do not have any conflicts of interest.
44

45
46 **Patient consent:** In order to participate into the present study a written informed consent was
47
48 obtained from adult participants (18 years and above), and assent and consent were requested
49
50 from adolescents and the parents/ guardians of participants below 18 yrs. No personal
51
52 participant's information is included in the results text, figures and tables.
53

54
55
56 **Ethical approval:** Ethical clearance was obtained from Muhimbili University of Health and
57
58 Allied Sciences (MUHAS), Senate Research and Publication Committee, with reference
59
60

number DA.282/298/01.C/. The MNH administration provided permission to conduct the study.

Availability of data and materials: All relevant data generated and analyzed during this study are available from the corresponding author on reasonable request.

Provenance and peer review: Not commissioned; externally peer reviewed.

REFERENCES

1. Schilder AGM, Chonmaitree T, Cripps AW, Rosenfeld RM, Casselbrant ML, Haggard MP, et al. Otitis media. *Nat Publ Gr.* 2016;16063(6):1–19.
2. Atkinson H, Wallis S, Coatesworth AP. Acute otitis media. *Postgrad Med.* 2015;127(4):386–90.
3. Mushi MF, Mwalutende AE, Gilyoma JM, Chalya PL, Seni J, Mirambo MM, et al. Predictors of disease complications and treatment outcome among patients with chronic suppurative otitis media attending a tertiary hospital , Mwanza Tanzania. *BMC Ear, Nose Throat Disord.* 2016;16(1):1–8.
4. Mwambete KD, Eulambius M. High Prevalence of Antibiotic-Resistant Otitis Media–Associated Bacterial Flora of Asymptomatic People Living with HIV at Morogoro Hospital, Tanzania. *J Int Assoc Provid AIDS Care.* 2018;17:1–8.
5. Mushi MF, Buname G, Bader O, Groß U, Mshana SE. *Aspergillus fumigatus* carrying TR34 / L98H resistance allele causing complicated suppurative otitis media in Tanzania : Call for improved diagnosis of fungi in sub-Saharan Africa. *BMC Infect Dis.* 2016;16(464):16–21.
6. Minja BM, Machemba A. Prevalence of otitis media, hearing impairment and cerumen impaction among school children in rural and urban Dar es Salaam, Tanzania. *Int J*

- 1
2
3 Pediatr Otorhinolaryngol. 1996;37(1):29–34.
4
5
6 7. Sinha A, Mohapatra LN. Otomycosis - A clinical and mycological study. Indian J
7
8 Otolaryngol. 1961;13(3):128–37.
9
10
11 8. Vaidya K, Madhup SK, Shrestha BL, Gautam A, Tuladha NR. Bacteriological and
12
13 Mycological profile of Chronic Suppurative Otitis Media among patients visiting
14
15 Dhulikhel Hospital. Ann Clin Chem Lab Med. 2015;1(1):37–41.
16
17
18 9. Martin TJ, Kerschner JE, Flanary VA. Fungal causes of otitis externa and
19
20 tympanostomy tube otorrhea. Int J Pediatr Otorhinolaryngol. 2005;69(11):1503–8.
21
22
23
24 10. Kumar A. Fungal spectrum in otomycosis patients. JK Sci. 2005;7(3):152–5.
25
26
27 11. Hall JW, Bouchard J, Bookstaver PB, Haldeman MS, Kishimbo P, Mbwaji G, et al.
28
29 The Mbeya Antimicrobial Stewardship Team: Implementing Antimicrobial
30
31 Stewardship at a Zonal-Level Hospital in Southern Tanzania. Pharmacy.
32
33 2020;8(2):107.
34
35
36
37 12. Seni J, Mapunjo SG, Wittenauer R, Valimba R, Stergachis A, Werth BJ, et al.
38
39 Antimicrobial use across six referral hospitals in Tanzania: A point prevalence survey.
40
41 BMJ Open. 2020;10(12):1–9.
42
43
44 13. NPS Medicinewise. Antibiotic resistance Antibiotic resistance. Prev Control [Internet].
45
46 2010;(July):2005–6. Available from:
47
48 [http://www.nps.org.au/__data/assets/pdf_file/0009/318879/NPSMW-antibiotic-](http://www.nps.org.au/__data/assets/pdf_file/0009/318879/NPSMW-antibiotic-resistance-the-facts.pdf)
49
50 resistance-the-facts.pdf
51
52
53
54 14. Testing S. M100 Performance Standards for Antimicrobial.
55
56
57 15. Abraham ZS, Ntunaguzi D, Kahinga AA, Mapondella KB, Massawe ER, Nkuwi EJ, et
58
59 al. Prevalence and etiological agents for chronic suppurative otitis media in a tertiary
60

- 1
2
3 hospital in Tanzania. *BMC Res Notes*. 2019;12(429):1–6.
4
5
6 16. Pavani K, Krishnamurthy S, Swetha KS, Supriya PS. Chronic Suppurative Otitis
7
8 Media (CSOM): Evaluation of fungal and aerobic bacterial agents and antibiotic
9
10 sensitivity pattern of the bacterial isolates. *Int J Med Microbiol Trop Dis*.
11
12 2020;5(4):214–7.
13
14
15 17. Aduda DSO, Macharia IM, Mugwe P, Oburra H, Farragher B, Brabin B, et al.
16
17 Bacteriology of chronic suppurative otitis media (CSOM) in children in Garissa
18
19 district, Kenya: A point prevalence study. *Int J Pediatr Otorhinolaryngol*.
20
21 2013;77(7):1107–11.
22
23
24
25 18. Kumar D, Agrawal A, Kumar S, Gupta N. “ A Study of the Microbiological Profile of
26
27 CSOM in A Tertiary Care Centre of North India .” *J Dent Med Sci*. 2019;18(5):20–4.
28
29
30
31 19. Uddén F, Filipe M, Reimer Å, Paul M, Matuschek E, Thegerström J, et al. Aerobic
32
33 bacteria associated with chronic suppurative otitis media in Angola. *Infect Dis*
34
35 *Poverty*. 2018;7(1):1–10.
36
37
38
39 20. Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: Aetiology, clinical features
40
41 and therapy. *Mycoses*. 2012;55(5):404–9.
42
43
44 21. Kiakojuri K, Armaki MT, Rajabnia R, Pournajaf A, Karami M, Khademian A, et al.
45
46 Outer ear infections in Iran: A review. *Open Access Maced J Med Sci*.
47
48 2019;7(7):1233–40.
49
50
51 22. Zlatian O. Etiology and pathogenesis of chronic suppurative otitis media. *Bluestone*
52
53 *kena*. 2007;13(1):16–7.
54
55
56 23. Viswanatha B, Naseeruddin K. Fungal infections of the ear in immunocompromised
57
58 host: A review. *Mediterr J Hematol Infect Dis*. 2011;3(1):1–4.
59
60

- 1
2
3 24. Shuaib Kayode A, Kayode Rashaq A, Tayo I, Viswanatha B, Naseeruddin K. A
4
5 Prospective Analysis of Otomycosis in a Tertiary Care Hospital. *Int J Trop Dis.*
6
7 2020;3(1):1–8.
8
9
- 10
11 25. Endaylalu K, Abera B, Mulu W. Extended spectrum beta lactamase producing bacteria
12
13 among outpatients with ear infection at FelegeHiwot Referral Hospital, North West
14
15 Ethiopia. *PLoS One* [Internet]. 2020;15(9 September):1–14. Available from:
16
17 <http://dx.doi.org/10.1371/journal.pone.0238891>
18
19
- 20
21 26. Allam AAE, Tantawy AEE, Mohamed KAE, El ghamrey NAM, Morad EA, El Shafei
22
23 MAE. Short Communication: Otitis externa in a tertiary care hospital in Zagazig,
24
25 Egypt: Isolated pathogens and their antibiotic sensitivity patterns. *African J Clin Exp*
26
27 *Microbiol.* 2019;21(1):60.
28
29
- 30
31 27. Argaw-Denboba A, Abejew AA, Mekonnen AG. Antibiotic-resistant bacteria are
32
33 major threats of otitis media in wollo area, northeastern Ethiopia: A ten-year
34
35 retrospective analysis. *Int J Microbiol.* 2016;2016(8724671):1–9.
36
37
- 38
39 28. Anghelina F, Zlatian O, Ciolofan MS, Calina D, Docea AO, Hainarosie R, et al.
40
41 Bacteriological profiles and antibiotic susceptibility patterns in complicated bacterial
42
43 infections of the ears, nose and throat. *Rev Chim.* 2019;70(12):4426–31.
44
45
- 46
47 29. Seid A, Deribe F, Ali K, Kibru G. Bacterial otitis media in all age group of patients
48
49 seen at Dessie referral hospital, North East Ethiopia. *Egypt J Ear, Nose, Throat Allied*
50
51 *Sci.* 2013;14(2):73–8.
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1: Types of ear infection among study participants at MNH

The figure illustrates the distribution of ear infections among patients presenting with signs and symptoms of ear infection attending the otorhinolaryngology clinic at MNH (N=255). OM, OE, and CSOM stand for otitis media, otitis externa, and chronic suppurative otitis media, respectively.

Figure 2A-C: Distribution of bacterial isolates

The figure depicts the distribution of bacteria spp isolated among patients with ear infections attending the otorhinolaryngology clinic at MNH (n=131)(A). According to the type of ear infection (n=131), where OM (otitis media), OE(otitis externa), and CSOM (chronic suppurative otitis media) (B). Distribution of ESBL-producing bacteria among isolated gram-negative bacteria in patients attending the otorhinolaryngology clinic at MNH (n = 61) (C).

Tables

Table 1: Socio-demographic characteristics of the study participants (N=255)	
Variables	Frequency (N) and Percentage (%)/Median(IQR)
Median age (years)	31 (15 - 49)
Sex	
Male	134 (52.5)
Female	121 (47.5)
Occupation	
Self-employed	56 (22.0)
Civil servants	62 (24.3)
Retired	49 (19.2)
Unemployed	88 (33.5)
Education	
Primary	75 (29.4)
Secondary	59 (23.1)
College	84 (32.9)
Illiterate	37 (14.5)

Residence	
Within Dar es Salaam	215 (84.3)
Outside Dar es Salaam	40 (15.7)

Table 2: Baseline clinical and risk behavioral characteristics of the study participants (N=255)


Patients characteristics	Frequency (N) and Percentage (%) / Median (IQR) (%)
Median Duration of ear infection (days)	210 (21-1095)
Nasal discharge/blockage	
Yes	85 (33.3)
No	170 (66.7)
Recurrent URTI	
Yes	72 (28.2)
No	183 (71.8)
Use of hearing aid	
Yes	2 (0.8)
No	253 (99.2)
Earphone use	
Yes	41 (16.1)
No	214 (83.9)
Swimming	
Yes	8 (3.1)
No	247 (96.9)
Cotton bud use	
Yes	112 (43.9)
No	143 (56.1)
Sharp object use	
Yes	60 (23.5)
No	195 (76.5)
Ear cleaning habit	
Yes	119 (46.7)
No	136 (53.3)
Cerumen impaction	
Yes	45 (17.6)
No	210 (82.4)

Table 3: Antimicrobial resistance pattern for isolated bacteria




ANTIBIOTIC	Bacteria isolates								Over all (N=129)
	<i>S.aureus</i> (N=36)	<i>Pseudomonas aeruginosa</i> (N=32)	<i>Klebsiella spp</i> (N=20)	<i>Acinetobacter spp</i> (N=10)	<i>Enterobacter spp</i> (N=6)	<i>E. coli</i> (N=8)	<i>Proteus spp</i> (N=12)	<i>Citrobacter spp</i> (N=5)	
Amikacin	NA	8(25)	4(20)	2(20)	3(50)	2(25)	1(8)	2(40)	22(24)
Sulfamethoxazole									
Trimethoprim	20(56)	NA	8(40)	1(10)	4(66)	6(75)	3(25)	4(80)	46(47)
Gentamicin	13(36)	6(19)	9(45)	1(10)	1(17)	1(13)	7(58)	1(20)	39(30)
Ciprofloxacin	11(31)	11(34)	1(5)	0(0)	2(33)	2(25)	1(8)	0(0)	28(22)
Amoxicillin									
Clavulanic acid	NA	NA	18(90)	10(100)	5(83)	8(100)	11(92)	5(100)	57(93)
Ceftriaxone	NA	NA	9(45)	5(50)	3(50)	5(63)	6(50)	3(60)	31(51)
Ceftazidime	NA	24(75)	14(70)	7(70)	4(66)	5(63)	10(83)	4(80)	68(73)
Cefotaxime	NA	NA	9(45)	8(80)	3(50)	5(63)	6(50)	5(100)	36(73)
Meropenem	NA	2(6)	0(0)	1(10)	0(0)	0(0)	1(8)	0(0)	4(4.3)
Erythromycin	32(89)	NA	NA	NA	NA	NA	NA	NA	32(89)
Clindamycin	9(25)	NA	NA	NA	NA	NA	NA	NA	9(25)
Levofloxacin	16(44)	NA	NA	NA	NA	NA	NA	NA	16(44)

Footnote: NA: Indicates not applicable

review only



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	5-7
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	5-8
		(e) Describe any sensitivity analyses	8
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	5
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	5
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	10-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Etiology of ear infection and antimicrobial susceptibility pattern among patients attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania: A hospital-based cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-068359.R1
Article Type:	Original research
Date Submitted by the Author:	04-Mar-2023
Complete List of Authors:	Shangali, Aminiel; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology; Mwanza University, Department of Microbiology and Immunology Kamori, Doreen; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Massawe, Willybroad; Muhimbili National Hospital, Department of Otorhinolaryngology Masoud, Salim; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Kibwana, Upendo; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Mwingwa, Anthony G.; Kilimanjaro Christian Medical Centre, Department of Microbiology and Immunology Manisha, Anselmo; Mwanza University, Department of Microbiology and Immunology Mwandigha, Ambele M.; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Mirambo, Mariam M; Catholic University of Health and Allied Sciences, Department of Microbiology and Immunology Mshana, Stephen E.; Catholic University of Health and Allied Sciences, Department of Microbiology and Immunology Manyahi, Joel; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Majigo, Mtebe; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology
Primary Subject Heading:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology, Infectious diseases
Keywords:	Microbiology < PATHOLOGY, MYCOLOGY, BACTERIOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **1 Etiology of ear infection and antimicrobial susceptibility pattern among patients**
4
5 **2 attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania:**
6
7 **3 A hospital-based cross-sectional study**
8
9
10
11
12

13 **5 Authors**
14
15

16 Aminiel Shangali^{1,3}, Doreen Kamori^{1,*}, Willybroad Massawe², Salim Masoud¹, Upendo O.
17 Kibwana¹, Anthony G. Mwingwa¹, Anselmo Manisha³, Ambele M. Mwandigha¹, Mariam
18 Mirambo⁴, Stephen E. Mshana⁴, Joel Manyahi¹, Mtebe V. Majigo¹
19
20
21
22

23 **9 Affiliation**
24
25

26 ¹ Department of Microbiology and Immunology, Muhimbili University of Health and Allied
27 Sciences, Dar es Salaam, Tanzania; ² Department of Otorhinolaryngology, Muhimbili
28 National Hospital, Dar es Salaam, Tanzania; ³ Department of Microbiology and Immunology,
29 Mwanza University, Mwanza, Tanzania; ⁴ Department of Microbiology and Immunology,
30 Catholic University of Health and Allied Sciences, Mwanza, Tanzania
31
32
33
34
35
36
37
38

39 **15 Email addresses.**
40

41 AS: arshangali@gmail.com	42 AM: anselmomanisha@gmail.com
43 DK: doreenkamori@gmail.com	44 AMM: ambelemawazo@gmail.com
45 WM: dwmassay@gmail.com	46 MM: mmmirambo@gmail.com
47 SM: salimsmasoud@gmail.com	48 SEM: stephen72mshana@gmail.com
49 UOK: pendokibwana@gmail.com	50 JM: manyahijoel@yahoo.com
51 AGM: anthonymwingwa@gmail.com	52 MVM: mmajigo@gmail.com

53 **28 *Correspondence:**
54

55 Doreen Kamori (MD, Ph.D.)
56 Muhimbili University of Health and Allied Sciences, P.O Box 65001, Dar es Salaam,
57 Tanzania, Phone number: +255 711 954 661, Email: doreenkamori@gmail.com
58 ORCID ID: <http://orcid.org/0000-0001-5162-6554>
59
60

1
2
3 33 **Keywords:** Ear infection, resistance, antimicrobial susceptibility pattern.
4

5
6 34 **ABSTRACT**
7

8 35 **OBJECTIVES:** To determine the etiological pathogens causing ear infections and their
9
10 36 antimicrobial susceptibility patterns among patients with ear complaints at a tertiary hospital
11
12
13 37 in Dar es Salaam.
14

15
16 38 **DESIGN:** Hospital-based cross-sectional study.
17

18
19 39 **SETTINGS:** Otorhinolaryngology clinic at Muhimbili National Hospital, Dar es Salaam,
20
21 40 Tanzania.
22

23
24 41 **PARTICIPANTS:** Patients presenting with signs and symptoms of ear infection.
25

26
27 42 **MAIN OUTCOME MEASURE:** Bacteria and fungi isolated from ear swab specimens of
28
29 43 patients presenting with signs and symptoms of ear infection; and antimicrobial susceptibility
30
31 44 patterns of isolated bacteria.
32

33
34
35 45 **RESULTS:** Two hundred fifty-five participants were enrolled, with a median age of 31 years
36
37 46 and an interquartile range of 15- 49. Otitis externa was the predominant type of ear infection,
38
39 47 accounting for 45.1%. We observed positive bacteria culture in 53.3% of study participants,
40
41 48 in which 41% of isolates were obtained from patients with chronic suppurative otitis media
42
43 49 (CSOM). Moreover, *S. aureus* (27.3%) and *P. aeruginosa* (24.2%) were the most frequently
44
45 50 isolated bacteria, while *Candida* spp, 12(63.8%), and *Aspergillus* spp, 9(36.2%) were the
46
47 51 only isolated fungi. Furthermore, we report that 93% of isolated *Enterobacterales* were
48
49 52 resistant to amoxicillin /clavulanic acid, and 73% were resistant to ceftazidime. In addition,
50
51 53 we detected 34.4% extended-spectrum beta-lactamase-producing *Enterobacterales* (ESBL-
52
53 54 PE) and 44.4% methicillin-resistance *Staphylococcus aureus* (MRSA). We also found that
54
55 55 22% of the bacteria isolates were resistant to ciprofloxacin, a primary topical antibiotic used
56
57 56 in managing ear infections.
58
59
60

1
2
3 57 **CONCLUSIONS:** The findings from this study reveal that the leading etiological agent of
4
5 58 ear infection is bacteria. Furthermore, our findings show a significant proportion of ESBL-PE
6
7 59 and MRSA-causing ear infections. Hence, detecting multidrug-resistant bacteria is crucial to
8
9 60 improving ear infection management.
10
11
12

13 **Strength and Limitation of the study**
14

- 15 62 • The present study has some strengths, we report the common bacterial and fungi
16
17 63 etiology of ear infection in our study setting.
18
19
20 64 • Notably, the study has revealed the antimicrobial susceptibility patterns that are useful
21
22 65 in guiding the choice of empirical treatment in similar settings with limited resources
23
24 66 and comparable geographic, demographic, and social characteristics.
25
26
27
28 67 • The present study has some limitations; some fungal (molds) isolates were not
29
30 68 identified to species level, and
31
32
33 69 • Anaerobic culture was not performed.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

An ear infection is among the leading cause of deafness in many developing countries. Unfortunately, most patients with ear infections in resource-limited settings delay seeking medical attention; hence, usually present with complications (1). Bacteria are the leading pathogens of ear infection, whereby, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, and Klebsiella species are the dominant bacteria causing ear infection globally (1–6). In addition, *Candida* spp and *Aspergillus* spp are predominant fungal isolates responsible for ear infections (7–10). However, due to limited diagnostic opportunities, fungal ear infections are often undiagnosed, especially in resource-limited countries, including Tanzania (5,6).

Most practitioners in our settings tend to treat ear infections empirically or adhere to the Standard Treatment Guideline (STG) without considering laboratory investigation and antimicrobial susceptibility testing (AST) results. This has created a gap in managing most ear infections, which raises the risk of acquiring multidrug-resistant bacteria (11,12). When first-line antibiotics cannot treat diseases, more costly antibiotics must be utilized. This consequently affects patients' treatment options, resulting in prolonged hospital stays and increased healthcare costs, which impacts families' financial burden and quality of life (13). Furthermore, there needs to be more data on the effectiveness of empirical treatment in managing ear infections in Tanzania. However, experience based on the clinic's patient return rate after initial treatment for ear infections, it appears that a considerable number of patients return to the clinic with the same problem. This suggests that relying solely on empirical treatment methods may not be effective in treating ear infections. Hence this warrants further research to investigate the antimicrobial susceptibility patterns of bacteria isolated in ear infections to improve the outcome of ear infections following appropriate empirical treatment.

1
2
3 96 Etiological studies of ear infections are essential to guide the choice of an effective antibiotic
4
5 97 and monitor bacterial patterns and their varying antimicrobial susceptibilities. This is crucial
6
7
8 98 for risk analysis, mitigation measures, and logistical plans. Therefore, the present study aimed
9
10 99 to determine the etiological pathogens and antimicrobial susceptibility patterns of bacteria
11
12 100 causing ear infections. The data obtained, if used, will strengthen the prevention and control
13
14 101 measures and update the management and treatment options for ear infections. Also, the
15
16
17 102 information will serve as a baseline for countrywide surveillance of antibiotic resistance.

103 **2. Materials and Methods**

104 **Study design and settings**

105 We conducted a hospital-based cross-sectional study from March to July 2021 in the
106 otorhinolaryngology clinic at Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania.
107 MNH is the leading national referral hospital, research center, and a university teaching
108 hospital. It is the largest tertiary healthcare facility in Tanzania. The hospital has a capacity of
109 1,500 beds, attending from 1,000 to 1,200 outpatients per week and admitting from 1,000 to
110 1,200 inpatients per week. The otorhinolaryngology department has inpatient and outpatient
111 units; about 20 to 30 patients attend the outpatient clinic per day.

112 **Study participants**

113 The study included patients attending the otorhinolaryngology clinic with signs and
114 symptoms of ear infection, such as accumulation of fluid in the middle ear, bulging of the
115 eardrum, ear pain, ear itching, perforation of the eardrum, and ear discharge (otorrhea). We
116 excluded patients with other hearing disorders unrelated to infection (congenital
117 malformations, physical head injury) and those on regular checkups.

118 **Sample size and sampling procedure**

1
2
3 119 The study sample size was estimated using a Kish Leslie formula (1965) for a cross-sectional
4
5 120 study considering the prevalence of 62.1% reported previously by Moshi et al. in a study
6
7 121 conducted in a tertiary hospital in Mwanza city, Tanzania (3). The minimum sample size was
8
9 122 241 participants; considering the 5% non-response rate, we obtained a sample size of 255
10
11 123 participants.
12
13
14
15 124

17 125 **Data collection**

18
19 126 Data collection was conducted by two trained research assistants (RAs) and an ear, nose, and
20
21 127 throat (ENT) surgeon; briefly, a structured questionnaire was administered to the participants
22
23 128 by two RAs. RAs used the questionnaire to collect demographic data (age, sex, marital status,
24
25 129 occupation, and education) and behavioral risk characteristics (swimming, frequent use of
26
27 130 earphones, cotton buds, sharp objects, and cigarette smoking). In addition, the participants'
28
29 131 clinical information, including the type of ear infection, use of antibiotics, nasal congestion or
30
31 132 blockage, recurrent upper respiratory tract infection (URTI), and cerumen impaction, were
32
33 133 also collected from the patient's medical records and during a physical examination by ENT
34
35 134 surgeon. In this study, CSOM was diagnosed when there is persistent otorrhea from the ear
36
37 135 for at least 3-12 weeks despite appropriate medical treatment or when there is a persistent
38
39 136 eardrum perforation with otorrhea for more than three months. This chronicity of otorrhea
40
41 137 distinguishes CSOM from acute otitis media, a short-term middle ear infection with acute
42
43 138 onset and rapid resolution.
44
45
46
47
48
49

50 139 **Specimen collection**

51
52 140 The ENT surgeon collected specimens with precaution to prevent contamination. The sterile
53
54 141 swab was used to clear the oozing pus from the patient's ear; another sterile swab was then
55
56 142 used to collect fresh pus. The collected specimens were kept at room temperature in Stuart
57
58 143 transport media before processing at Central Pathology Laboratory (CPL).
59
60

144 **Isolation and identification**

145 Upon arrival in the laboratory, specimens were processed for culture and identification. Each
146 specimen was inoculated on selective and non-selective media; Chocolate agar (CA), Sheep-
147 Blood agar (sBA), MacConkey agar (MCA), and Sabouraud dextrose agar (SDA). We used
148 CA to isolate fastidious bacteria, such as *H. influenzae* and *S. pneumoniae*, the frequent
149 etiological agents of ear infection. MCA was used as a selective and differential medium for
150 Gram-negative bacteria, and BA was used as a general-purpose medium. SDA was used for
151 the isolation of fungal species. We incubated MCA in an aerobic environment and BA and
152 CA in a 5% CO₂ environment at 37°C for 18 to 24 hours.

153 Bacterial isolates were identified by interpreting colonial morphologies, microscopic
154 examination (Gram stain), and biochemical tests. The catalase and coagulase tests were
155 performed for Gram-positive bacteria, while Kligler Iron Agar, Sulfur Indole Motility (SIM),
156 citrate, and urease tests were for gram-negative bacteria. Further, phenotypical identification
157 and confirmation of Gram-negative bacterial isolates were performed by Analytical Profile
158 Index tests, API 20E and API 20NE.

159 For fungal isolates, growth on the SDA plate was used preliminary to classify mold or yeast
160 based on the colonial morphology and color. A germ tube test was used to identify *Candida*
161 *albicans*. Additionally, Lactophenol cotton blue was used for molds to identify the conidial
162 spore in *Aspergillus spp.*

163 **Antimicrobial susceptibility testing**

164 Antibiotic susceptibility test (AST) for bacterial isolates was performed using the Kirby
165 Bauer disc diffusion method on Mueller-Hinton Agar (MHA), and MHA supplemented with
166 5% blood for *S. pneumonia* following the 2021 Clinical and Laboratory Standard Institute

1
2
3 167 (CLSI) guidelines. Zones of inhibition were measured using a ruler in millimeters and
4
5 168 interpreted as susceptible, resistant, or intermediate according to the 2021 CLSI guideline.

6
7
8
9 169 The antibiotic discs used were; ciprofloxacin (5µg), trimethoprim/ sulphamethoxazole
10
11 170 (1.25/23.75µg), gentamycin (10µg), clindamycin (2 µg), erythromycin (15µg,) for gram-
12
13 171 positive bacteria. Ciprofloxacin (5µg), trimethoprim/ sulphamethoxazole (1.25/23.75µg),
14
15 172 gentamycin (10µg), meropenem (10µg), amoxicillin/ clavulanic acid (20µg), ceftriaxone
16
17 173 (30µg) and ceftazidime (30µg) for *Enterobacterales* and *Acinetobacter spp.* Ciprofloxacin
18
19 174 (5µg), gentamycin (10µg), meropenem (10µg) and ceftazidime (30µg) for *Pseudomonas spp.*

20
21
22
23
24 175 Standard methods were used to identify MRSA using cefoxitin (30µg) disc in which resistant
25
26 176 isolates were considered MRSA positive. In addition, ESBL-PE screening was done using
27
28 177 ceftazidime (30 µg) and cefotaxime (30µg) antibiotic discs, and if resistant, ESBL-PE
29
30 178 confirmation was done by the double-disc synergy method (14).

31 32 33 34 179 **Quality control**

35
36 180 The reference organisms and reagents were clearly and uniquely labeled, dated, and stored at
37
38 181 optimal conditions. The room, incubator, and refrigerator temperatures were monitored daily.
39
40 182 The culture media were prepared following the manufacturer's guidelines and internal
41
42 183 standard operating procedures and tested for performance and sterility.

43 44 45 46 47 184 **Data Analysis**

48
49 185 The data was analyzed using SPSS version 23 software. Continuous variables were
50
51 186 summarized as the median and interquartile range (IQR), whereas percentages and
52
53 187 proportions were used to describe categorical variables. The resistance rate was obtained by
54
55 188 computing the number of bacteria that resisted a specific drug over a total number of isolated
56
57 189 bacterial species. AST intermediate results were regarded as resistant.
58
59
60

1
2
3 190 **Patient and public involvement**
4
5

6 191 Patients and the public were not involved in this research's design, conduct, reporting, or
7
8 192 dissemination plans.
9

10
11 193

12
13
14 194 **3. Results**

15
16 195 **Participants' demographic, clinical, and risk behavior characteristics**

17
18 196 Two hundred fifty-five participants were recruited; 52.5% (134/255) were males. The median
19
20 197 age was 31 years (IQR: 15- 49). Most participants (30.2%) were students, 32.9% had a
21
22 198 college education, and 15.7% were from outside Dar es Salaam region (Table 1).
23
24

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

Table 1: Socio-demographic characteristics of the study participants (N=255)	
Variables	Frequency (N) and Percentage (%)/Median (IQR)
Median age (years)	31 (15 - 49)
Sex	
Male	134 (52.5)
Female	121 (47.5)
Occupation	
Self-employed	56 (22.0)
Civil servants	62 (24.3)
Retired	49 (19.2)
Unemployed	88 (33.5)
Education	
Primary	75 (29.4)
Secondary	59 (23.1)
College	84 (32.9)
Illiterate	37 (14.5)
Residence	
Within Dar es Salaam	215 (84.3)
Outside Dar es Salaam	40 (15.7)

52 199

53
54
55 200 The median duration of ear infections was 210 days (IQR: 21-1095). Otitis externa (OE) was
56
57 201 the most common type of ear infection, accounting for 45.1% (115/255), followed by Chronic
58
59 202 Suppurative Otitis Media (CSOM) (41.2%) (Figure 1). Around 49% of the participants with
60

203 ear infections had a history of antibiotic use, whereby ciprofloxacin ear drop was the most
 204 prescribed topical antibiotic. Additionally, 33.3% of the study participants had nasal
 205 congestion/blockage/discharge, and 28.2% had recurrent URTI (Table 2).

Table 2: Baseline clinical and risk behavioral characteristics of the study participants (N=255)	
Patient characteristics	Frequency (N) and Percentage (%)/Median (IQR) (%)
Median Duration of ear infection (days)	210 (21-1095)
Nasal discharge/blockage	
Yes	85 (33.3)
No	170 (66.7)
Recurrent URTI	
Yes	72 (28.2)
No	183 (71.8)
Use of hearing aid	
Yes	2 (0.8)
No	253 (99.2)
Earphone use	
Yes	41 (16.1)
No	214 (83.9)
Swimming	
Yes	8 (3.1)
No	247 (96.9)
Cotton bud use	
Yes	112 (43.9)
No	143 (56.1)
Sharp object use	
Yes	60 (23.5)
No	195 (76.5)
Ear cleaning habit	
Yes	119 (46.7)
No	136 (53.3)
Cerumen impaction	
Yes	45 (17.6)
No	210 (82.4)

206

207 **Distribution of bacterial and fungal isolates causing ear infections**

208 In this study, 136 out of 255 (53.3%) participants had a positive aerobic culture for either
 209 bacterial or fungal pathogen, whereby 10.3% (14/136) of participants had a polymicrobial

1
2
3 210 infection (mixed growth of either two different bacteria or bacterial and fungal infection). A
4
5 211 total of 150 isolates (bacteria and fungi) were identified, of which 87.3% (131/150) were
6
7 212 bacteria. Of the isolated bacteria, Gram-negative, 71.0% (93/131) were predominant.
8
9

10
11 213 The predominant bacterial isolates were *S. aureus*, 27.5% (36/131), followed by
12
13 214 *Pseudomonas aeruginosa*, 24.4% (32/131) (Figure 2A). On the other hand, *Candida spp*
14
15 215 accounted for 63.2% (12/19) of the isolated fungi (data not shown). Moreover, 41% of
16
17 216 isolates were obtained from chronic suppurative otitis media (CSOM) patients. Further
18
19 217 stratification of isolated pathogens by type of ear infection showed that *S. aureus* 16/131
20
21 218 (12.2%) was the most prevalent bacterium in OE patients, whereas *P. aeruginosa* 22/131
22
23 219 (16.8%) predominated in CSOM patients (Figure 2B).
24
25
26
27

28
29 220 In the present study, 34.4% (21/61) of the Enterobacterales, excluding *P. aeruginosa*, were
30
31 221 extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE); and *Klebsiella*
32
33 222 *spp* was predominant, accounting for 33.3% (7/21) of the ESBL-PE isolates (Figure 2C). On
34
35 223 the other hand, 44.4% (16/36) of the *S. aureus* species were MRSA (data not shown).
36
37
38

39 224 **Antimicrobial susceptibility pattern of bacterial isolates**

40
41
42 225 Almost all (93%) isolated Enterobacterales were resistant to amoxicillin/clavulanic acid,
43
44 226 more so *E. coli* and *Acinetobacter spp* were 100% resistant. Also, 73% of isolated bacteria
45
46 227 were resistant to ceftazidime (data not shown), whereby *P. aeruginosa* had the highest
47
48 228 resistance rate of 75%. In addition, 43% of isolated bacteria were resistant to trimethoprim-
49
50 229 sulfamethoxazole (data not shown), whereby *E. coli* was leading with a 75% resistance rate.
51
52 230 Sulfamethoxazole-trimethoprim resistance rates ranged from 57% to 100% among ESBL
53
54 231 producers, higher than 29% to 100% among non-ESBL producers. Moreover, 14.6% (6/41)
55
56 232 of the non-ESBL-PE bacteria were resistant to all the third-generation cephalosporins, and all
57
58
59
60

233 non-ESBL-PE isolates were sensitive to meropenem. *S. aureus* had an 89% resistance rate to
 234 erythromycin. However, MRSA isolates were more resistant to sulfamethoxazole-
 235 trimethoprim (81%) and gentamicin (50%) than non-MRSA isolates 35% and 25% for
 236 sulfamethoxazole-trimethoprim and gentamicin, respectively. In the present study, we report
 237 that resistance to ciprofloxacin, a primary topical antibiotic used to manage ear infections, is
 238 22%. Most isolated bacteria had a low resistance rate against meropenem (4%) (Table 3).

239

ANTIBIOTIC	Bacteria isolates							
	<i>S. aureus</i> (N=36)	<i>Pseudomonas aeruginosa</i> (N=32)	<i>Klebsiella spp</i> (N=20)	<i>Acinetobacter spp</i> (N=10)	<i>Enterobacter spp</i> (N=6)	<i>E. coli</i> (N=8)	<i>Proteus spp</i> (N=12)	<i>Citrobacter spp</i> (N=5)
Amikacin	NA	8(25)	4(20)	2(20)	3(50)	2(25)	1(8)	2(40)
Sulfamethoxazole trimethoprim	20(56)	NA	8(40)	1(10)	4(66)	6(75)	3(25)	4(80)
Gentamicin	13(36)	6(19)	9(45)	1(10)	1(17)	1(13)	7(58)	1(20)
Ciprofloxacin	11(31)	11(34)	1(5)	0(0)	2(33)	2(25)	1(8)	0(0)
Amoxicillin /clavulanic acid	NA	NA	18(90)	10(100)	5(83)	8(100)	11(92)	5(100)
Ceftriaxone	NA	NA	9(45)	5(50)	3(50)	5(63)	6(50)	3(60)
Ceftazidime	NA	24(75)	14(70)	7(70)	4(66)	5(63)	10(83)	4(80)
Cefotaxime	NA	NA	9(45)	8(80)	3(50)	5(63)	6(50)	5(100)
Meropenem	NA	2(6)	0(0)	1(10)	0(0)	0(0)	1(8)	0(0)
Erythromycin	32(89)	NA	NA	NA	NA	NA	NA	NA
Clindamycin	9(25)	NA	NA	NA	NA	NA	NA	NA
Cefoxitin	16(44)	NA	NA	NA	NA	NA	NA	NA

240 Footnote: NA: Indicates not applicable

241

242 4. Discussion

243 Understanding the etiology of ear infections and resistance pattern is crucial in planning
 244 interventions and managing ear infections. The results indicate a substantial proportion of ear
 245 infections, with bacteria as the primary etiological agent. Most isolated bacteria were resistant
 246 to third-generation cephalosporins, sulfamethoxazole-trimethoprim, and
 247 amoxicillin/clavulanic acid. Gram-positive bacteria were highly resistant to erythromycin.
 248 The two antibiotics that worked the best were ciprofloxacin and meropenem. The results

249 imply the need to review ear infection management and the selection of an efficient
250 antibiotic.

251 The study found that many ear infections are of bacterial etiology. The finding is similar to
252 studies done in Tanzania by Kennedy M et al. (2019) in Morogoro (4), Zephania A et al.
253 (2019) in Dar es Salaam (15), Martha M et al. (2016) in Mwanza (3) and other studies in
254 Kenya and India (16,17). Furthermore, we observed that *S. aureus* and *Pseudomonas*
255 *aeruginosa* are ear infections' leading bacterial etiological agents, similar to previous studies
256 in Tanzania, Nigeria, Angola, Kenya, and India (3,17–19). In addition, the present study
257 found *Candida spp* and *Aspergillus spp* the fungal spp, causing ear infections consistent with
258 previous findings in Tanzania and elsewhere (Nigeria, Iran, Ethiopia, Egypt, India) (3–5,20–
259 22). Nonetheless, the contribution of fungi etiology in ear infections in the present study was
260 expected because many individuals had risk behaviors for fungal ear infections, including
261 excessive use of eardrops containing antibiotics, regular cleaning of ears, and swimming.
262 Antibiotic overuse promotes the growth of fungi, and the regular ear cleaning habit removes
263 cerumen and exposes ears to fungi colonization and, subsequently, infection (23,24).

264 The current study revealed a high proportion of MRSA (44.4%) and ESBL-PE (34.4%). In
265 addition, our study showed *Klebsiella spp* (33.3%) as the dominant ESBL-PE. The higher
266 proportion of MRSA and ESBL-PE coincides with studies done in Tanzania by Martha M et
267 al. among patients with chronic suppurative otitis media infection and another study in India
268 (3,16). The greater inclination for self- and empirically prescribing antibiotics without
269 considering laboratory culture and sensitivity may explain the higher proportion of ESBL and
270 MRSA. Furthermore, an increased tendency for people to visit hospital facilities due to
271 chronic ear infections can also explain the high incidence of ESBL and MRSA, which raises
272 the danger of exposure to MDR bacteria. Additionally, the tendency to use inanimate objects

1
2
3 273 to remove earwax can be attributed to the increased proportion of ESBL and MRSA, as these
4
5 274 inanimate objects are often found in environments that may be contaminated with ESBL-
6
7
8 275 producing bacteria and MRSA (25).
9

10
11 276 Almost all isolated bacteria (93%) were resistant to amoxicillin/clavulanic acid. Nearly three-
12
13 277 quarters of gram-negative bacteria were resistant to ceftazidime, and about half were resistant
14
15 278 to trimethoprim-sulfamethoxazole. On the other hand, 89% of isolate gram-positive were
16
17 279 resistant to erythromycin. ESBL-PE and MRSA isolates were resistant to the most common
18
19 280 antimicrobial agents compared to non-MRSA and non-ESBL-PE. The resistance patterns
20
21 281 found in the current study are similar to those reported in other studies in Tanzania, Kenya,
22
23 282 Ethiopia, India, Egypt, and Romania (3,4,17,18,26–29). The frequent use of these antibiotics
24
25 283 to treat various bacterial infections in our setting and the likelihood that most bacterial
26
27 284 species have developed resistance to antimicrobial drugs over time may contribute to the
28
29 285 observed resistance pattern.
30
31

32
33 286 In the present study, most isolated bacteria were sensitive to meropenem and ciprofloxacin.
34
35 287 Ciprofloxacin is a drug of choice for ear infections as per standard treatment guidelines in our
36
37 288 setting. The fact that meropenem is infrequently used to treat ear infections may explain the
38
39 289 high sensitivity rate. Surprisingly, we observed that ciprofloxacin is still effective despite
40
41 290 being prescribed often in our setting for treating ear infections. There is no clinical rationale
42
43 291 for why quinolones are still more effective in treating ear infections. However, these results
44
45 292 assure that quinolones are still beneficial as first-line topical antibiotics for ear infections.
46
47

293 **Study Limitations**

- 51
52
53 294 • We could not identify the fungi isolates to species level. This is due to insufficient
54
55 295 funding and the availability of resources. However, all fungi isolates were stored
56
57 296 appropriately for future testing.
58
59
60

- 1
2
3 297 • Due to financial constraints and lack of equipment, it was also impossible to isolate
4
5 298 anaerobic bacteria from the collected pus specimen
6
7

8 299 **5. CONCLUSION**

10 300 The results of this study indicate that bacteria are the most common cause of ear infections in
11
12 301 our context. Furthermore, we report that many multidrug-resistant bacteria (ESBL-PE and
13
14 302 MRSA) are implicated in causing ear infections. Therefore, antimicrobial susceptibility
15
16
17 303 testing is crucial to guide clinicians on appropriately managing ear infections in our setting.
18
19

20 304 **Acknowledgements:** The authors wish to acknowledge the Muhimbili National Hospital
21
22 305 (MNH) administration and the Mwanza University, Tanzania, for their support. The authors
23
24 306 are also grateful to all the study participants, the otorhinolaryngology clinic staff, and CPL
25
26
27 307 staff at MNH.
28
29

30 308 **Contributors:** AS, DK, and WM contributed to the conceptualization, data collection, and
31
32 309 analysis study. AS, DK, WM, UK, AGM, AM, SM, AMM, MM, SEM, JM, and MM were
33
34 310 involved in manuscript preparation. JM and MM profoundly reviewed the manuscript. AS is
35
36 311 the guarantor of the study. The corresponding author attests that all listed authors meet
37
38 312 authorship criteria and that no one meeting the criteria has been omitted. The lead author (the
39
40 313 manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent
41
42 314 account of the study being reported; that no important aspects of the study have been omitted;
43
44 315 and that any discrepancies from the study as planned (and, if relevant, registered) have been
45
46
47 316 explained.
48
49

50
51
52 317 **Funding:** No funding was received for this study.
53
54

55 318 **Competing interests:** The authors do not have any conflicts of interest.
56
57
58
59
60

1
2
3 319 **Patient consent:** To participate in the present study, written informed consent was obtained
4
5 320 from adult participants (18 years and above). Assent and consent were requested from
6
7 321 adolescents and the parents/ guardians of participants below 18 yrs. The results text, figures,
8
9 322 and tables include no personal participant information.
10
11
12

13 323 **Ethical approval:** Ethical clearance was obtained from Muhimbili University of Health and
14
15 324 Allied Sciences (MUHAS), Senate Research and Publication Committee, with reference
16
17 325 number DA.282/298/01.C/. The MNH administration provided permission to conduct the
18
19 326 study.
20
21
22

23 327 **Availability of data and materials:** All relevant data generated and analyzed during this
24
25 328 study are available from the corresponding author upon reasonable request.
26
27

28 329 **Provenance and peer review:** Not commissioned; externally peer-reviewed.
29
30

31 330 REFERENCES

- 32
33 331 1. Schilder AGM, Chonmaitree T, Cripps AW, Rosenfeld RM, Casselbrant ML, Haggard
34
35 332 MP, et al. Otitis media. *Nat Publ Gr.* 2016;16063(6):1–19.
36
37
38 333 2. Atkinson H, Wallis S, Coatesworth AP. Acute otitis media. *Postgrad Med.*
39
40 334 2015;127(4):386–90.
41
42
43 335 3. Mushi MF, Mwalutende AE, Gilyoma JM, Chalya PL, Seni J, Mirambo MM, et al.
44
45 336 Predictors of disease complications and treatment outcome among patients with
46
47 337 chronic suppurative otitis media attending a tertiary hospital , Mwanza Tanzania. *BMC*
48
49 338 *Ear, Nose Throat Disord.* 2016;16(1):1–8.
50
51
52
53 339 4. Mwambete KD, Eulambius M. High Prevalence of Antibiotic-Resistant Otitis Media–
54
55 340 Associated Bacterial Flora of Asymptomatic People Living with HIV at Morogoro
56
57 341 Hospital, Tanzania. *J Int Assoc Provid AIDS Care.* 2018;17:1–8.
58
59
60

- 1
2
3 342 5. Mushi MF, Buname G, Bader O, Groß U, Mshana SE. *Aspergillus fumigatus* carrying
4
5 343 TR34 / L98H resistance allele causing complicated suppurative otitis media in
6
7 344 Tanzania : Call for improved diagnosis of fungi in sub-Saharan Africa. *BMC Infect*
8
9 345 *Dis.* 2016;16(464):16–21.
- 10
11
12
13 346 6. Minja BM, Machemba A. Prevalence of otitis media, hearing impairment and cerumen
14
15 347 impaction among school children in rural and urban Dar es Salaam, Tanzania. *Int J*
16
17 348 *Pediatr Otorhinolaryngol.* 1996;37(1):29–34.
- 19
20 349 7. Sinha A, Mohapatra LN. Otomycosis - A clinical and mycological study. *Indian J*
21
22 350 *Otolaryngol.* 1961;13(3):128–37.
- 23
24
25 351 8. Vaidya K, Madhup SK, Shrestha BL, Gautam A, Tuladha NR. Bacteriological and
26
27 352 Mycological profile of Chronic Suppurative Otitis Media among patients visiting
28
29 353 Dhulikhel Hospital. *Ann Clin Chem Lab Med.* 2015;1(1):37–41.
- 30
31
32
33 354 9. Martin TJ, Kerschner JE, Flanary VA. Fungal causes of otitis externa and
34
35 355 tympanostomy tube otorrhea. *Int J Pediatr Otorhinolaryngol.* 2005;69(11):1503–8.
- 36
37
38 356 10. Kumar A. Fungal spectrum in otomycosis patients. *JK Sci.* 2005;7(3):152–5.
- 39
40
41 357 11. Hall JW, Bouchard J, Bookstaver PB, Haldeman MS, Kishimbo P, Mbwanji G, et al.
42
43 358 The Mbeya Antimicrobial Stewardship Team: Implementing Antimicrobial
44
45 359 Stewardship at a Zonal-Level Hospital in Southern Tanzania. *Pharmacy.*
46
47 360 2020;8(2):107.
- 48
49
50
51 361 12. Seni J, Mapunjo SG, Wittenauer R, Valimba R, Stergachis A, Werth BJ, et al.
52
53 362 Antimicrobial use across six referral hospitals in Tanzania: A point prevalence survey.
54
55 363 *BMJ Open.* 2020;10(12):1–9.
- 56
57
58
59 364 13. NPS Medicinewise. Antibiotic resistance Antibiotic resistance. *Prev Control* [Internet].
60

- 1
2
3 365 2010;(July):2005–6. Available from:
4
5 366 http://www.nps.org.au/__data/assets/pdf_file/0009/318879/NPSMW-antibiotic-
6
7
8 367 [resistance-the-facts.pdf](http://www.nps.org.au/__data/assets/pdf_file/0009/318879/NPSMW-antibiotic-resistance-the-facts.pdf)
9
10
11 368 14. Testing S. M100 Performance Standards for Antimicrobial.
12
13
14 369 15. Abraham ZS, Ntunaguzi D, Kahinga AA, Mapondella KB, Massawe ER, Nkuwi EJ, et
15
16 370 al. Prevalence and etiological agents for chronic suppurative otitis media in a tertiary
17
18 371 hospital in Tanzania. *BMC Res Notes*. 2019;12(429):1–6.
19
20
21 372 16. Pavani K, Krishnamurthy S, Swetha KS, Supriya PS. Chronic Suppurative Otitis
22
23 373 Media (CSOM): Evaluation of fungal and aerobic bacterial agents and antibiotic
24
25 374 sensitivity pattern of the bacterial isolates. *Int J Med Microbiol Trop Dis*.
26
27
28 375 2020;5(4):214–7.
29
30
31 376 17. Aduda DSO, Macharia IM, Mugwe P, Oburra H, Farragher B, Brabin B, et al.
32
33 377 Bacteriology of chronic suppurative otitis media (CSOM) in children in Garissa
34
35 378 district, Kenya: A point prevalence study. *Int J Pediatr Otorhinolaryngol*.
36
37
38 379 2013;77(7):1107–11.
39
40
41 380 18. Kumar D, Agrawal A, Kumar S, Gupta N. “ A Study of the Microbiological Profile of
42
43 381 CSOM in A Tertiary Care Centre of North India .” *J Dent Med Sci*. 2019;18(5):20–4.
44
45
46 382 19. Uddén F, Filipe M, Reimer Å, Paul M, Matuschek E, Thegerström J, et al. Aerobic
47
48 383 bacteria associated with chronic suppurative otitis media in Angola. *Infect Dis*
49
50 384 *Poverty*. 2018;7(1):1–10.
51
52
53
54 385 20. Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: Aetiology, clinical features
55
56 386 and therapy. *Mycoses*. 2012;55(5):404–9.
57
58
59 387 21. Kiakojuri K, Armaki MT, Rajabnia R, Pournajaf A, Karami M, Khademian A, et al.
60

- 1
2
3 388 Outer ear infections in Iran: A review. *Open Access Maced J Med Sci*.
4
5 389 2019;7(7):1233–40.
6
7
8 390 22. Zlatian O. Etiology and pathogenesis of chronic suppurative otitis media. *Bluestone*
9
10 391 *kena*. 2007;13(1):16–7.
11
12
13 392 23. Viswanatha B, Naseeruddin K. Fungal infections of the ear in immunocompromised
14
15 393 host: A review. *Mediterr J Hematol Infect Dis*. 2011;3(1):1–4.
16
17
18 394 24. Shuaib Kayode A, Kayode Rashaq A, Tayo I, Viswanatha B, Naseeruddin K. A
19
20 395 Prospective Analysis of Otomycosis in a Tertiary Care Hospital. *Int J Trop Dis*.
21
22 396 2020;3(1):1–8.
23
24
25 397 25. Endaylalu K, Abera B, Mulu W. Extended spectrum beta lactamase producing bacteria
26
27 398 among outpatients with ear infection at FelegeHiwot Referral Hospital, North West
28
29 399 Ethiopia. *PLoS One* [Internet]. 2020;15(9 September):1–14. Available from:
30
31 400 <http://dx.doi.org/10.1371/journal.pone.0238891>
32
33
34 401 26. Allam AAE, Tantawy AEE, Mohamed KAE, El ghamrey NAM, Morad EA, El Shafei
35
36 402 MAE. Short Communication: Otitis externa in a tertiary care hospital in Zagazig,
37
38 403 Egypt: Isolated pathogens and their antibiotic sensitivity patterns. *African J Clin Exp*
39
40 404 *Microbiol*. 2019;21(1):60.
41
42
43 405 27. Argaw-Denboba A, Abejew AA, Mekonnen AG. Antibiotic-resistant bacteria are
44
45 406 major threats of otitis media in wollo area, northeastern Ethiopia: A ten-year
46
47 407 retrospective analysis. *Int J Microbiol*. 2016;2016(8724671):1–9.
48
49
50 408 28. Anghelina F, Zlatian O, Ciolofan MS, Calina D, Docea AO, Hainarosie R, et al.
51
52 409 Bacteriological profiles and antibiotic susceptibility patterns in complicated bacterial
53
54 410 infections of the ears, nose and throat. *Rev Chim*. 2019;70(12):4426–31.
55
56
57
58
59
60

- 1
2
3 411 29. Seid A, Deribe F, Ali K, Kibru G. Bacterial otitis media in all age group of patients
4
5
6 412 seen at Dessie referral hospital, North East Ethiopia. Egypt J Ear, Nose, Throat Allied
7
8 413 Sci. 2013;14(2):73–8.
9

10
11 414
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3 416 **Figure legends**
4
5

6 417 **Figure 1: Types of ear infection among study participants at MNH**
7

8 418 The figure illustrates the distribution of ear infections among patients presenting with signs
9 and symptoms of ear infection attending the otorhinolaryngology clinic at MNH (N=255).
10
11 419
12
13 420 OM, OE, and CSOM stand for otitis media, otitis externa, and chronic suppurative otitis
14
15 421 media, respectively.
16
17


18 422 **Figure 2A-C: Distribution of bacterial isolates**
19

20
21 423 The figure depicts the distribution of bacteria spp isolated among patients with ear infections
22 attending the otorhinolaryngology clinic at MNH (n=131)(A). According to the type of ear
23 424 infection (n=131), where OM (otitis media), OE(otitis externa), and CSOM (chronic
25 425 suppurative otitis media) (B). Distribution of ESBL-producing bacteria among isolated gram-
26
27 426
28
29 427 negative bacteria in patients attending the otorhinolaryngology clinic at MNH (n = 61) (C).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41


A



B



C



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

STROBE Statement

	Page Number	Description
Title and abstract	1-3	<p>(a) Etiology of ear infection and antimicrobial susceptibility pattern among patients attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania (hospital-based cross-sectional study)</p> <hr/> <p>(b) OBJECTIVES: To determine the etiological pathogens causing ear infections and their antimicrobial susceptibility patterns among patients with ear complaints at a tertiary hospital in Dar es Salaam.</p> <p>DESIGN: Hospital-based cross-sectional study.</p> <p>SETTINGS: Otorhinolaryngology clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania.</p> <p>PARTICIPANTS: Patients presenting with signs and symptoms of ear infection.</p> <p>MAIN OUTCOME MEASURE: Bacteria and fungi isolated from ear swab specimens of patients presenting with signs and symptoms of ear infection; and antimicrobial susceptibility patterns of isolated bacteria.</p> <p>RESULTS: Two hundred fifty-five participants were enrolled, with a median age of 31 years and an interquartile range of 15- 49. Otitis externa was the predominant type of ear infection, accounting for 45.1%. We observed positive bacteria culture in 53.3% of study participants, in which 41% of isolates were obtained from patients with chronic suppurative otitis media (CSOM). Moreover, <i>S. aureus</i> (27.3%) and <i>P. aeruginosa</i> (24.2%) were the most frequently isolated bacteria, while <i>Candida spp</i>, 12(63.8%), and <i>Aspergillus spp</i>, 9(36.2%) were the only isolated fungi. We report that 93% of isolated Enterobacterales were resistant to amoxicillin /clavulanic acid, and 73% were resistant to ceftazidime. In addition, we detected 34.4% extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE) and 44.4% methicillin-resistance <i>Staphylococcus aureus</i> (MRSA). We also detected resistance to ciprofloxacin a primary topical antibiotic used in management of ear infection is 22%.</p> <p>CONCLUSIONS: The findings from this study reveal that the leading etiological agent of ear infection is bacteria. Furthermore, our findings show a significant proportion of ESBL-PE and MRSA-causing ear infections. Hence, detecting multidrug-resistant bacteria is crucial to improving ear infection management.</p>
<hr/>		
Introduction		
Background/rationale	4-5	<p>An ear infection is among the leading cause of deafness in many developing countries. Unfortunately, most patients with ear infections in resource-limited settings delay seeking medical attention; hence, usually present with complications. Bacteria are the leading pathogens of ear infection whereby, <i>Staphylococcus aureus</i>, <i>Pseudomonas aeruginosa</i>, <i>Proteus mirabilis</i>, and <i>Klebsiella species</i> are the dominant bacteria species causing ear infection globally. In addition, <i>Candida spp</i> and <i>Aspergillus spp</i> are predominant fungal isolates</p>

responsible for ear infections. However, fungal ear infections are often undiagnosed due to limited diagnostic opportunities, especially in resource-limited countries, including Tanzania.

Most practitioners in our settings tend to treat ear infections empirically or adhere to the Standard Treatment Guideline (STG) without considering laboratory investigation and Antimicrobial susceptibility testing (AST) results. This has created a gap in managing most ear infections, which raises the risk of acquiring multidrug-resistant bacteria. When first-line antibiotics cannot treat infections, more costly antibiotics must be utilized. This consequently affects patients' treatment options, resulting in prolonged hospital stays and increased healthcare costs, which impacts families' financial burden and quality of life.

Etiological studies of ear infections are important to guide the choice of an effective antibiotic and monitoring bacterial patterns and their varying antimicrobial susceptibilities. This is crucial for risk analysis, mitigation measures, and logistical plans. Therefore, the present study aimed to determine the etiological pathogens and antimicrobial susceptibility patterns of bacteria causing ear infections. The data obtained will be used to strengthen the prevention and control measures and to update the management and treatment options for ear infections. Also, the information will serve as a baseline for countrywide surveillance of antibiotic resistance.

Objectives	4	1. To determine bacterial species and proportion of fungi causing ear infection among patients attending otorhinolaryngology clinic at MNH. 2. To determine the antimicrobial susceptibility patterns of bacteria isolates causing ear infection among patients attending otorhinolaryngology clinic at MNH
Methods		
Study design	5	This is a hospital-based cross-sectional study
Setting	5	The study was carried out at the Muhimbili National Hospital (MNH), in Dar es Salaam, Tanzania, in the otorhinolaryngology clinic from March to July 2021. A standardized questionnaire and patient's medical records were used to obtain participant's social demographic, behavioural and clinical information. Ear swab was collected, then culture and antimicrobial susceptibility testing was performed for the isolated bacteria species.
Participants	5	The study included all the patients attending otorhinolaryngology clinic at MNH with ear complaints such as accumulation of fluid in the middle ear, bulging of the eardrum, ear pain, ear itching, perforation of the eardrum and ear discharge (otorrhea) and participants who consented or assented to participate in the study. We excluded patients with other hearing disorders (congenital malformations, physical head injury, etc.). And Patients who are on regular check-ups
Variables	6	Outcome variables -Ear infection Independent variables - demographic data (age, sex, marital status, occupation, and education) and behavioural risk characteristics (swimming, frequent use of earphones, cotton buds, sharp objects, and cigarette smoking). Clinical information, including the type of ear infection, use of antibiotics, nasal congestion or blockage, recurrent upper respiratory tract infection (URTI), and cerumen impaction
Data sources/	6	Outcome variables – Laboratory (Culture and sensitivity) was the source of data

1 2 3 4 5	measurement		for outcome variables, where by percentage was used to summarize the bacteria and fungi species isolates and the magnitude of resistance for each isolated bacteria.
6 7 8 9 10 11 12 13 14 15 16 17 18	Bias	8	Efforts to address potential sources of Bias Results from this study depended on good practice in the pre-analytic stage including correct procedures during sample collection, proper labelling of the specimen and safe transportation of the sample including proper storage and temperature (2°C– 8°C) to the laboratory and this was guided by standard operating procedures. Clinical and demographic data for each study participant was obtained by using a standardized questionnaire and patients' medical records. The use of a standard questionnaire is said to be reliable because all participants were subjected to the same questionnaire when evaluating the factors associated with ear infection.
19 20 21 22 23 24 25 26 27 28 29 30 31	Study size	5	The sample size was estimated by using the Kish Leslie formula (1965) using the prevalence of 62% obtained from a study done in Tanzania. $N = \frac{Z^2 P (1-P)}{D^2}$ Whereby Z=standard deviation of the normal distribution = 1.96 (confidence level at 95%) P=prevalence 62.1% (5) D=Margin of error 6% N=251 The minimum required sample size was 251 participants with ear infections.
32 33 34 35	Quantitative variables	8	Quantitative variables were summarized by calculating measures such as mean, median standard deviation, and quartiles to summarize the central tendency and dispersion of the data
36	Results		
37 38 39 40 41 42 43 44 45 46 47 48 49	Descriptive data	9-10	(a) Two hundred fifty-five participants were recruited; 52.5% (134/255) were males. The median age was 31 years (IQR: 15- 49). The majority (30.2%) of participants were students, 32.9% had a college education, and 15.7% were from outside Dar es Salaam region (Table 1). The median duration of ear infections was 210 days (IQR: 21-1095). Otitis externa (OE) was the most common type of ear infection, accounting for 45.1% (115/255), followed by Chronic Suppurative Otitis Media (CSOM) (41.2%). Around 49% of the participants with ear infections had a history of antibiotic use, whereby ciprofloxacin ear drop was the most prescribed topical antibiotic. Additionally, 33.3% of the study participants had nasal congestion/blockage/discharge, and 28.2% had recurrent URTI (b) No participant with missing variable
51 52 53 54 55 56 57 58 59 60	Outcome data	10-12	In this study, 136 out of 255 (53.3%) participants had a positive aerobic culture for either bacterial or fungal pathogen. A total of 150 isolates (bacteria and fungi) were identified, of which 87.3% (131/150) were bacteria. Of the isolated bacteria, Gram-negative, 71.0% (93/131) were predominant. The predominant bacterial isolates were <i>S. aureus</i> , 27.5% (36/131), followed by <i>Pseudomonas aeruginosa</i> , 24.4% (32/131). On the other hand, <i>Candida spp</i> accounted for 63.2% (12/19) of the isolated fungi (data not shown). Further stratification of isolated pathogens by type of ear infection showed that <i>S. aureus</i> 16/131 (12.2%) was the most prevalent bacterium in OE patients, whereas <i>P.</i>

aeruginosa 22/131 (16.8%) predominated in CSOM patients. In the present study 34.4% (21/61) of the *Enterobacteriales*, excluding *Pseudomonas aeruginosa*, were extended-spectrum beta-lactamase producing *Enterobacteriales* (ESBL-PE); and *Klebsiella spp* was predominant, accounting for 33.3% (7/21) of the ESBL-PE isolates. On the other hand, 44.4% (16/36) of the *S.aureus* species were MRSA.

Almost all (93%) isolated Enterobacteriales were resistant to amoxicillin/clavulanic acid, more so *E. coli* and *Acinetobacter spp* were 100% resistant. Also, 73% of isolated bacteria were resistant to ceftazidime, whereby *Pseudomonas aeruginosa* had the highest resistance rate of 75%. In addition, 43% of isolated bacteria were resistant to trimethoprim-sulfamethoxazole, whereby *E.coli* was leading with a 75% resistance rate.

Discussion

Key results

53.3% of research participants reported positive bacteria cultures. *S. aureus* (27.3%) and *P.aeruginosa* (24.2%) were the most frequently isolated bacteria, whereas *Candida spp.* 12(63.8%), and *Aspergillus spp.* 9(36.2%) were the only isolated fungi. 73% of the identified Enterobacteriales were resistant to ceftazidime, while 93% were resistant to amoxicillin/clavulanic acid. Furthermore, we identified 44.4% methicillin-resistant *Staphylococcus aureus* (MRSA) and 34.4% extended-spectrum beta-lactamase-producing Enterobacteriales (ESBL-PE)

Limitations

14-15

1. The present study was not able to identify the fungi isolates to species level. This is due to insufficient funding and availability of resources. To mitigate this all fungi isolates were stored appropriately for future testing to specie level.
2. Due to financial constraints and lack of equipment, it was also not possible to isolate anaerobic bacteria from the collected pus specimen

Interpretation

12-14

According to the study many ear infections are of bacterial etiology, *S. aureus* and *Pseudomonas aeruginosa* are the most commonly isolated bacteria. The majority of isolated bacteria were resistant to amoxicillin/clavulanic acid, sulfamethoxazole-trimethoprim, Erythromycin and third-generation cephalosporins. The most effective antibiotics were ciprofloxacin and meropenem. The findings suggest that ear infection management procedures and the choice of an effective antibiotic need to be reviewed. The results are consistent with research conducted in Tanzania by Kennedy M. et al. (2019) in Morogoro, Zephania A. et al. (2019) in Dar es Salaam, Martha M. et al. (2016) in Mwanza, as well as research from Kenya and India.

The current study revealed a high proportion of MRSA (44.4%) and ESBL-PE (34.4%). ESBL-PE and MRSA isolates were resistant to the most common antimicrobial agents compared to non-MRSA and non-ESBL-PE. In addition, our study showed *Klebsiella spp* (33.3%) as the dominant ESBL-PE. The higher proportion of MRSA and ESBL-PE coincide with other studies in Tanzania, Kenya, Ethiopia, India, Egypt, and Romania. The greater inclination for self- and empirically prescribing antibiotics without considering laboratory culture and sensitivity may explain the higher proportion of ESBL and MRSA. The high incidence of ESBL and MRSA can also be explained by an increased inclination for people to visit hospital facilities due to chronic ear infection, which raises the danger of exposure to MDR bacteria. Additionally, the tendency to use inanimate

objects to remove earwax can be attributed to the increased proportion of ESBL and MRSA, as these inanimate objects are often found in environments that may be contaminated with ESBL-producing bacteria and/or MRSA

Ciprofloxacin is a drug of choice for ear infections as per standard treatment guidelines in our setting. The fact that meropenem is infrequently used to treat ear infections may explain the high sensitivity rate. Surprisingly, we observed that ciprofloxacin is still effective despite being prescribed often in our setting for treating ear infections. There is no clinical rationale as to why quinolones are still more effective in treating ear infections, but these results assure that quinolones are still beneficial as first-line topical antibiotics for ear infections.

Generalisability	According to the study's findings, bacteria are the most common etiological factor in ear infections. Additionally, our results indicate that a significant percentage of ear infections are caused by ESBL-PE and MRSA. Therefore, identifying multidrug-resistant bacteria is essential to enhancing the management of ear infections. The study has also identified patterns of antimicrobial susceptibility that are helpful in guiding the selection of empirical treatment in environments with limited resources and comparable geographic, demographic, and social characteristics.
Other information	
Funding	15 No funding was received for this study.

BMJ Open

Etiology of ear infection and antimicrobial susceptibility pattern among patients attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania: A hospital-based cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-068359.R2
Article Type:	Original research
Date Submitted by the Author:	14-Mar-2023
Complete List of Authors:	Shangali, Aminiel; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology; Mwanza University, Department of Microbiology and Immunology Kamori, Doreen; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Massawe, Willybroad; Muhimbili National Hospital, Department of Otorhinolaryngology Masoud, Salim; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Kibwana, Upendo; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Mwingwa, Anthony G.; Kilimanjaro Christian Medical Centre, Department of Microbiology and Immunology Manisha, Anselmo; Mwanza University, Department of Microbiology and Immunology Mwandigha, Ambele M.; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Mirambo, Mariam M; Catholic University of Health and Allied Sciences, Department of Microbiology and Immunology Mshana, Stephen E.; Catholic University of Health and Allied Sciences, Department of Microbiology and Immunology Manyahi, Joel; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology Majigo, Mtebe; Muhimbili University of Health and Allied Sciences, Department of Microbiology and Immunology
Primary Subject Heading:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology, Infectious diseases
Keywords:	Microbiology < PATHOLOGY, MYCOLOGY, BACTERIOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **1 Etiology of ear infection and antimicrobial susceptibility pattern among patients**
4
5 **2 attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania:**
6
7 **3 A hospital-based cross-sectional study**
8
9

10
11
12
13 **5 Authors**
14
15

16 Aminiel Shangali^{1,3}, Doreen Kamori^{1,*}, Willybroad Massawe², Salim Masoud¹, Upendo O.
17
18 Kibwana¹, Anthony G. Mwingwa¹, Anselmo Manisha³, Ambele M. Mwandigha¹, Mariam
19
20 Mirambo⁴, Stephen E. Mshana⁴, Joel Manyahi¹, Mtebe V. Majigo¹
21
22

23
24 **9 Affiliation**
25

26
27 ¹ Department of Microbiology and Immunology, Muhimbili University of Health and Allied
28
29 Sciences, Dar es Salaam, Tanzania; ² Department of Otorhinolaryngology, Muhimbili
30
31 National Hospital, Dar es Salaam, Tanzania; ³ Department of Microbiology and Immunology,
32
33 Mwanza University, Mwanza, Tanzania; ⁴ Department of Microbiology and Immunology,
34
35 Catholic University of Health and Allied Sciences, Mwanza, Tanzania
36
37
38

39 **15 Email addresses.**
40

41 AS: arshangali@gmail.com 22 AM: anselmomanisha@gmail.com
42 DK: doreenkamori@gmail.com 23 AMM: ambelemawazo@gmail.com
43 WM: dwmassay@gmail.com 24 MM: mmmirambo@gmail.com
44 SM: salimsmasoud@gmail.com 25 SEM: stephen72mshana@gmail.com
45
46 UOK: pendokibwana@gmail.com 26 JM: manyahijoel@yahoo.com
47
48 AGM: anthonymwingwa@gmail.com 27 MVM: mmajigo@gmail.com
49
50

51 ***Correspondence:**
52

53 Doreen Kamori (MD, Ph.D.)
54
55 Muhimbili University of Health and Allied Sciences, P.O Box 65001, Dar es Salaam,
56
57 Tanzania, Phone number: +255 711 954 661, Email: doreenkamori@gmail.com
58
59 ORCID ID: <http://orcid.org/0000-0001-5162-6554>
60

1
2
3 33 **Keywords:** Ear infection, resistance, antimicrobial susceptibility pattern.
4

5
6 34 **ABSTRACT**
7

8 35 **OBJECTIVES:** To determine the etiological pathogens causing ear infections and their
9
10 36 antimicrobial susceptibility patterns among patients with ear complaints at a tertiary hospital
11
12
13 37 in Dar es Salaam.
14

15
16 38 **DESIGN:** Hospital-based cross-sectional study.
17

18
19 39 **SETTINGS:** Otorhinolaryngology clinic at Muhimbili National Hospital, Dar es Salaam,
20
21 40 Tanzania.
22

23
24 41 **PARTICIPANTS:** Patients presenting with signs and symptoms of ear infection.
25

26
27 42 **MAIN OUTCOME MEASURE:** Bacteria and fungi isolated from ear swab specimens of
28
29 43 patients presenting with signs and symptoms of ear infection; and antimicrobial susceptibility
30
31 44 patterns of isolated bacteria.
32

33
34
35 45 **RESULTS:** Two hundred fifty-five participants were enrolled, with a median age of 31 years
36
37 46 and an interquartile range of 15- 49. Otitis externa was the predominant type of ear infection,
38
39 47 accounting for 45.1%. We observed positive bacteria culture in 53.3% of study participants,
40
41 48 in which 41% of isolates were obtained from patients with chronic suppurative otitis media
42
43 49 (CSOM). Moreover, *S. aureus* (27.3%) and *P. aeruginosa* (24.2%) were the most frequently
44
45 50 isolated bacteria, while *Candida* spp, 12(63.8%), and *Aspergillus* spp, 9(36.2%) were the
46
47 51 only isolated fungi. Furthermore, we report that 93% of isolated *Enterobacterales* were
48
49 52 resistant to amoxicillin /clavulanic acid, and 73% were resistant to ceftazidime. In addition,
50
51 53 we detected 34.4% extended-spectrum beta-lactamase-producing *Enterobacterales* (ESBL-
52
53 54 PE) and 44.4% methicillin-resistance *Staphylococcus aureus* (MRSA). We also found that
54
55 55 22% of the bacteria isolates were resistant to ciprofloxacin, a primary topical antibiotic used
56
57 56 in managing ear infections.
58
59
60

1
2
3 57 **CONCLUSIONS:** The findings from this study reveal that the leading etiological agent of
4
5 58 ear infection is bacteria. Furthermore, our findings show a significant proportion of ESBL-PE
6
7 59 and MRSA-causing ear infections. Hence, detecting multidrug-resistant bacteria is crucial to
8
9 60 improving ear infection management.
10
11
12

13 **Strength and Limitation of the study**
14

- 15 62 • The present study has some strengths, we report the common bacterial and fungi
16
17 63 etiology of ear infection in our study setting.
18
19
20 64 • Notably, the study has revealed the antimicrobial susceptibility patterns that are useful
21
22 65 in guiding the choice of empirical treatment in similar settings with limited resources
23
24 66 and comparable geographic, demographic, and social characteristics.
25
26
27
28 67 • The present study has some limitations; some fungal (molds) isolates were not
29
30 68 identified to species level, and
31
32
33 69 • Anaerobic culture was not performed.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

An ear infection is among the leading cause of deafness in many developing countries. Unfortunately, most patients with ear infections in resource-limited settings delay seeking medical attention; hence, usually present with complications (1). Bacteria are the leading pathogens of ear infection, whereby, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, and Klebsiella species are the dominant bacteria causing ear infection globally (1–6). In addition, *Candida* spp and *Aspergillus* spp are predominant fungal isolates responsible for ear infections (7–10). However, due to limited diagnostic opportunities, fungal ear infections are often undiagnosed, especially in resource-limited countries, including Tanzania (5,6).

Most practitioners in our settings tend to treat ear infections empirically or adhere to the Standard Treatment Guideline (STG) without considering laboratory investigation and antimicrobial susceptibility testing (AST) results. This has created a gap in managing most ear infections, which raises the risk of acquiring multidrug-resistant bacteria (11,12). When first-line antibiotics cannot treat diseases, more costly antibiotics must be utilized. This consequently affects patients' treatment options, resulting in prolonged hospital stays and increased healthcare costs, which impacts families' financial burden and quality of life (13). Furthermore, there needs to be more data on the effectiveness of empirical treatment in managing ear infections in Tanzania. However, experience based on the clinic's patient return rate after initial treatment for ear infections, it appears that a considerable number of patients return to the clinic with the same problem. This suggests that relying solely on empirical treatment methods may not be effective in treating ear infections. Hence this warrants further research to investigate the antimicrobial susceptibility patterns of bacteria isolated in ear infections to improve the outcome of ear infections following appropriate empirical treatment.

1
2
3 96 Etiological studies of ear infections are essential to guide the choice of an effective antibiotic
4
5 97 and monitor bacterial patterns and their varying antimicrobial susceptibilities. This is crucial
6
7
8 98 for risk analysis, mitigation measures, and logistical plans. Therefore, the present study aimed
9
10 99 to determine the etiological pathogens and antimicrobial susceptibility patterns of bacteria
11
12 100 causing ear infections. The data obtained, if used, will strengthen the prevention and control
13
14 101 measures and update the management and treatment options for ear infections. Also, the
15
16
17 102 information will serve as a baseline for countrywide surveillance of antibiotic resistance.

103 **2. Materials and Methods**

104 **Study design and settings**

105 We conducted a hospital-based cross-sectional study from March to July 2021 in the
106 otorhinolaryngology clinic at Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania.
107 MNH is the leading national referral hospital, research center, and a university teaching
108 hospital. It is the largest tertiary healthcare facility in Tanzania. The hospital has a capacity of
109 1,500 beds, attending from 1,000 to 1,200 outpatients per week and admitting from 1,000 to
110 1,200 inpatients per week. The otorhinolaryngology department has inpatient and
111 outpatient units; about 20 to 30 patients attend the outpatient clinic per day.

112 **Study participants**

113 The study included patients attending the otorhinolaryngology clinic with signs and
114 symptoms of ear infection, such as accumulation of fluid in the middle ear, bulging of the
115 eardrum, ear pain, ear itching, perforation of the eardrum, and ear discharge (otorrhea). We
116 excluded patients with other hearing disorders unrelated to infection (congenital
117 malformations, physical head injury) and those on regular checkups.

118 **Sample size and sampling procedure**

1
2
3 119 The study sample size was estimated using a Kish Leslie formula (1965) for a cross-sectional
4
5 120 study considering the prevalence of 62.1% reported previously by Moshi et al. in a study
6
7 121 conducted in a tertiary hospital in Mwanza city, Tanzania (3). The minimum sample size was
8
9 122 241 participants; considering the 5% non-response rate, we obtained a sample size of 255
10
11 123 participants.
12
13
14
15 124

17 125 **Data collection**

18
19 126 Data collection was conducted by two trained research assistants (RAs) and an ear, nose, and
20
21 127 throat (ENT) surgeon; briefly, a structured questionnaire was administered to the participants
22
23 128 by two RAs. RAs used the questionnaire to collect demographic data (age, sex, marital status,
24
25 129 occupation, and education) and behavioral risk characteristics (swimming, frequent use of
26
27 130 earphones, cotton buds, sharp objects, and cigarette smoking). In addition, the participants'
28
29 131 clinical information, including the type of ear infection, use of antibiotics, nasal congestion or
30
31 132 blockage, recurrent upper respiratory tract infection (URTI), and cerumen impaction, were
32
33 133 also collected from the patient's medical records and during a physical examination by ENT
34
35 134 surgeon. In this study, CSOM was diagnosed when there is persistent otorrhea from the ear
36
37 135 for at least 3-12 weeks despite appropriate medical treatment or when there is a persistent
38
39 136 eardrum perforation with otorrhea for more than three months. This chronicity of otorrhea
40
41 137 distinguishes CSOM from acute otitis media, a short-term middle ear infection with acute
42
43 138 onset and rapid resolution.
44
45
46
47
48
49

50 139 **Specimen collection**

51
52 140 The ENT surgeon collected specimens with precaution to prevent contamination. The sterile
53
54 141 swab was used to clear the oozing pus from the patient's ear; another sterile swab was then
55
56 142 used to collect fresh pus. The collected specimens were kept at room temperature in Stuart
57
58 143 transport media before processing at Central Pathology Laboratory (CPL).
59
60

144 **Isolation and identification**

145 Upon arrival in the laboratory, specimens were processed for culture and identification. Each
146 specimen was inoculated on selective and non-selective media; Chocolate agar (CA), Sheep-
147 Blood agar (sBA), MacConkey agar (MCA), and Sabouraud dextrose agar (SDA). We used
148 CA to isolate fastidious bacteria, such as *H. influenzae* and *S. pneumoniae*, the frequent
149 etiological agents of ear infection. MCA was used as a selective and differential medium for
150 Gram-negative bacteria, and BA was used as a general-purpose medium. SDA was used for
151 the isolation of fungal species. We incubated MCA in an aerobic environment and BA and
152 CA in a 5% CO₂ environment at 37°C for 18 to 24 hours.

153 Bacterial isolates were identified by interpreting colonial morphologies, microscopic
154 examination (Gram stain), and biochemical tests. The catalase and coagulase tests were
155 performed for Gram-positive bacteria, while Kligler Iron Agar, Sulfur Indole Motility (SIM),
156 citrate, and urease tests were for gram-negative bacteria. Further, phenotypical identification
157 and confirmation of Gram-negative bacterial isolates were performed by Analytical Profile
158 Index tests, API 20E and API 20NE.

159 For fungal isolates, growth on the SDA plate was used preliminary to classify mold or yeast
160 based on the colonial morphology and color. A germ tube test was used to identify *Candida*
161 *albicans*. Additionally, Lactophenol cotton blue was used for molds to identify the conidial
162 spore in *Aspergillus spp.*

163 **Antimicrobial susceptibility testing**

164 Antibiotic susceptibility test (AST) for bacterial isolates was performed using the Kirby
165 Bauer disc diffusion method on Mueller-Hinton Agar (MHA), and MHA supplemented with
166 5% blood for *S. pneumonia* following the 2021 Clinical and Laboratory Standard Institute

1
2
3 167 (CLSI) guidelines. Zones of inhibition were measured using a ruler in millimeters and
4
5 168 interpreted as susceptible, resistant, or intermediate according to the 2021 CLSI guideline.

6
7
8
9 169 The antibiotic discs used were; ciprofloxacin (5µg), trimethoprim/ sulphamethoxazole
10
11 170 (1.25/23.75µg), gentamycin (10µg), clindamycin (2 µg), erythromycin (15µg,) for gram-
12
13 171 positive bacteria. Ciprofloxacin (5µg), trimethoprim/ sulphamethoxazole (1.25/23.75µg),
14
15 172 gentamycin (10µg), meropenem (10µg), amoxicillin/ clavulanic acid (20µg), ceftriaxone
16
17 173 (30µg) and ceftazidime (30µg) for *Enterobacterales* and *Acinetobacter spp.* Ciprofloxacin
18
19 174 (5µg), gentamycin (10µg), meropenem (10µg) and ceftazidime (30µg) for *Pseudomonas spp.*

20
21
22
23
24 175 Standard methods were used to identify MRSA using cefoxitin (30µg) disc in which resistant
25
26 176 isolates were considered MRSA positive. In addition, ESBL-PE screening was done using
27
28 177 ceftazidime (30 µg) and cefotaxime (30µg) antibiotic discs, and if resistant, ESBL-PE
29
30 178 confirmation was done by the double-disc synergy method (14).

31 32 33 34 179 **Quality control**

35
36 180 The reference organisms and reagents were clearly and uniquely labeled, dated, and stored at
37
38 181 optimal conditions. The room, incubator, and refrigerator temperatures were monitored daily.
39
40 182 The culture media were prepared following the manufacturer's guidelines and internal
41
42 183 standard operating procedures and tested for performance and sterility.

43 44 45 46 47 184 **Data Analysis**

48
49 185 The data was analyzed using SPSS version 23 software. Continuous variables were
50
51 186 summarized as the median and interquartile range (IQR), whereas percentages and
52
53 187 proportions were used to describe categorical variables. The resistance rate was obtained by
54
55 188 computing the number of bacteria that resisted a specific drug over a total number of isolated
56
57 189 bacterial species. AST intermediate results were regarded as resistant.
58
59
60

190 **Reporting Guideline**

191 This study adhered to the STROBE guidelines for cross-sectional studies, which provide a
 192 checklist for reporting observational studies. The checklist includes crucial elements that
 193 should be included in the report, such as the study design, participant selection, data
 194 collection, and statistical analysis. The authors have carefully reviewed the checklist to
 195 ensure that they incorporated each relevant item into the study design and analysis. The
 196 authors utilized a standardized data collection tool to collect information on all study
 197 participants and employed appropriate statistical methods to analyze the data and draw
 198 conclusions.

199 **Patient and public involvement**

200 Patients and the public were not involved in this research's design, conduct, reporting, or
 201 dissemination plans.

202

203 **3. Results**

204 **Participants' demographic, clinical, and risk behavior characteristics**

205 Two hundred fifty-five participants were recruited; 52.5% (134/255) were males. The median
 206 age was 31 years (IQR: 15- 49). Most participants (30.2%) were students, 32.9% had a
 207 college education, and 15.7% were from outside Dar es Salaam region (Table 1).

Table 1: Socio-demographic characteristics of the study participants (N=255)	
Variables	Frequency (N) and Percentage (%)/Median (IQR)
Median age (years)	31 (15 - 49)
Sex	
Male	134 (52.5)
Female	121 (47.5)
Occupation	
Self-employed	56 (22.0)
Civil servants	62 (24.3)

Retired	49 (19.2)
Unemployed	88 (33.5)
Education	
Primary	75 (29.4)
Secondary	59 (23.1)
College	84 (32.9)
Illiterate	37 (14.5)
Residence	
Within Dar es Salaam	215 (84.3)
Outside Dar es Salaam	40 (15.7)

208

209 The median duration of ear infections was 210 days (IQR: 21-1095). Otitis externa (OE) was
 210 the most common type of ear infection, accounting for 45.1% (115/255), followed by Chronic
 211 Suppurative Otitis Media (CSOM) (41.2%) (Figure 1). Around 49% of the participants with
 212 ear infections had a history of antibiotic use, whereby ciprofloxacin ear drop was the most
 213 prescribed topical antibiotic. Additionally, 33.3% of the study participants had nasal
 214 congestion/blockage/discharge, and 28.2% had recurrent URTI (Table 2).

Table 2: Baseline clinical and risk behavioral characteristics of the study participants (N=255)	
Patient characteristics	Frequency (N) and Percentage (%)/Median (IQR) (%)
Median Duration of ear infection (days)	210 (21-1095)
Nasal discharge/blockage	
Yes	85 (33.3)
No	170 (66.7)
Recurrent URTI	
Yes	72 (28.2)
No	183 (71.8)
Use of hearing aid	
Yes	2 (0.8)
No	253 (99.2)
Earphone use	
Yes	41 (16.1)
No	214 (83.9)
Swimming	
Yes	8 (3.1)
No	247 (96.9)
Cotton bud use	
Yes	112 (43.9)

No	143 (56.1)
Sharp object use	
Yes	60 (23.5)
No	195 (76.5)
Ear cleaning habit	
Yes	119 (46.7)
No	136 (53.3)
Cerumen impaction	
Yes	45 (17.6)
No	210 (82.4)

215

216 **Distribution of bacterial and fungal isolates causing ear infections**

217 In this study, 136 out of 255 (53.3%) participants had a positive aerobic culture for either
 218 bacterial or fungal pathogen, whereby 10.3% (14/136) of participants had a polymicrobial
 219 infection (mixed growth of either two different bacteria or bacterial and fungal infection). A
 220 total of 150 isolates (bacteria and fungi) were identified, of which 87.3% (131/150) were
 221 bacteria. Of the isolated bacteria, Gram-negative, 71.0% (93/131) were predominant.

222 The predominant bacterial isolates were *S. aureus*, 27.5% (36/131), followed by
 223 *Pseudomonas aeruginosa*, 24.4% (32/131) (Figure 2A). On the other hand, *Candida spp*
 224 accounted for 63.2% (12/19) of the isolated fungi (data not shown). Moreover, 41% of
 225 isolates were obtained from chronic suppurative otitis media (CSOM) patients. Further
 226 stratification of isolated pathogens by type of ear infection showed that *S. aureus* 16/131
 227 (12.2%) was the most prevalent bacterium in OE patients, whereas *P. aeruginosa* 22/131
 228 (16.8%) predominated in CSOM patients (Figure 2B).

229 In the present study, 34.4% (21/61) of the Enterobacterales, excluding *P. aeruginosa*, were
 230 extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE); and *Klebsiella*
 231 *spp* was predominant, accounting for 33.3% (7/21) of the ESBL-PE isolates (Figure 2C). On
 232 the other hand, 44.4% (16/36) of the *S. aureus* species were MRSA (data not shown).

233 Antimicrobial susceptibility pattern of bacterial isolates

234 Almost all (93%) isolated Enterobacterales were resistant to amoxicillin/clavulanic acid,
 235 more so *E. coli* and *Acinetobacter* spp were 100% resistant. Also, 73% of isolated bacteria
 236 were resistant to ceftazidime (data not shown), whereby *P. aeruginosa* had the highest
 237 resistance rate of 75%. In addition, 43% of isolated bacteria were resistant to trimethoprim-
 238 sulfamethoxazole (data not shown), whereby *E. coli* was leading with a 75% resistance rate.
 239 Sulfamethoxazole-trimethoprim resistance rates ranged from 57% to 100% among ESBL
 240 producers, higher than 29% to 100% among non-ESBL producers. Moreover, 14.6% (6/41)
 241 of the non-ESBL-PE bacteria were resistant to all the third-generation cephalosporins, and all
 242 non-ESBL-PE isolates were sensitive to meropenem. *S. aureus* had an 89% resistance rate to
 243 erythromycin. However, MRSA isolates were more resistant to sulfamethoxazole-
 244 trimethoprim (81%) and gentamicin (50%) than non-MRSA isolates 35% and 25% for
 245 sulfamethoxazole-trimethoprim and gentamicin, respectively. In the present study, we report
 246 that resistance to ciprofloxacin, a primary topical antibiotic used to manage ear infections, is
 247 22%. Most isolated bacteria had a low resistance rate against meropenem (4%) (Table 3).

248

Table 3: Antimicrobial resistance pattern for isolated bacteria

ANTIBIOTIC	Bacteria isolates							
	<i>S.aureus</i> (N=36)	<i>Pseudomonas</i> <i>aeruginosa</i> (N=32)	<i>Klebsiella</i> <i>spp</i> (N=20)	<i>Acinetobacter</i> <i>spp</i> (N=10)	<i>Enterobacter</i> <i>spp</i> (N=6)	<i>E. coli</i> (N=8)	<i>Proteus</i> <i>spp</i> (N=12)	<i>Citrobacter</i> <i>spp</i> (N=5)
Amikacin	NA	8(25)	4(20)	2(20)	3(50)	2(25)	1(8)	2(40)
Sulfamethoxazole trimethoprim	20(56)	NA	8(40)	1(10)	4(66)	6(75)	3(25)	4(80)
Gentamicin	13(36)	6(19)	9(45)	1(10)	1(17)	1(13)	7(58)	1(20)
Ciprofloxacin	11(31)	11(34)	1(5)	0(0)	2(33)	2(25)	1(8)	0(0)
Amoxicillin /clavulanic acid	NA	NA	18(90)	10(100)	5(83)	8(100)	11(92)	5(100)
Ceftriaxone	NA	NA	9(45)	5(50)	3(50)	5(63)	6(50)	3(60)
Ceftazidime	NA	24(75)	14(70)	7(70)	4(66)	5(63)	10(83)	4(80)
Cefotaxime	NA	NA	9(45)	8(80)	3(50)	5(63)	6(50)	5(100)
Meropenem	NA	2(6)	0(0)	1(10)	0(0)	0(0)	1(8)	0(0)
Erythromycin	32(89)	NA	NA	NA	NA	NA	NA	NA
Clindamycin	9(25)	NA	NA	NA	NA	NA	NA	NA
Cefoxitin	16(44)	NA	NA	NA	NA	NA	NA	NA

249 Footnote: NA: Indicates not applicable

250

251 4. Discussion

252 Understanding the etiology of ear infections and resistance pattern is crucial in planning
253 interventions and managing ear infections. The results indicate a substantial proportion of ear
254 infections, with bacteria as the primary etiological agent. Most isolated bacteria were resistant
255 to third-generation cephalosporins, sulfamethoxazole-trimethoprim, and
256 amoxicillin/clavulanic acid. Gram-positive bacteria were highly resistant to erythromycin.
257 The two antibiotics that worked the best were ciprofloxacin and meropenem. The results
258 imply the need to review ear infection management and the selection of an efficient
259 antibiotic.

260 The study found that many ear infections are of bacterial etiology. The finding is similar to
261 studies done in Tanzania by Kennedy M et al. (2019) in Morogoro (4), Zephania A et al.
262 (2019) in Dar es Salaam (15), Martha M et al. (2016) in Mwanza (3) and other studies in
263 Kenya and India (16,17). Furthermore, we observed that *S. aureus* and *Pseudomonas*
264 *aeruginosa* are ear infections' leading bacterial etiological agents, similar to previous studies
265 in Tanzania, Nigeria, Angola, Kenya, and India (3,17–19). In addition, the present study
266 found *Candida spp* and *Aspergillus spp* the fungal spp, causing ear infections consistent with
267 previous findings in Tanzania and elsewhere (Nigeria, Iran, Ethiopia, Egypt, India) (3–5,20–
268 22). Nonetheless, the contribution of fungi etiology in ear infections in the present study was
269 expected because many individuals had risk behaviors for fungal ear infections, including
270 excessive use of eardrops containing antibiotics, regular cleaning of ears, and swimming.
271 Antibiotic overuse promotes the growth of fungi, and the regular ear cleaning habit removes
272 cerumen and exposes ears to fungi colonization and, subsequently, infection (23,24).

1
2
3 273 The current study revealed a high proportion of MRSA (44.4%) and ESBL-PE (34.4%). In
4
5 274 addition, our study showed *Klebsiella* spp (33.3%) as the dominant ESBL-PE. The higher
6
7
8 275 proportion of MRSA and ESBL-PE coincides with studies done in Tanzania by Martha M et
9
10 276 al. among patients with chronic suppurative otitis media infection and another study in India
11
12 277 (3,16). The greater inclination for self- and empirically prescribing antibiotics without
13
14 278 considering laboratory culture and sensitivity may explain the higher proportion of ESBL and
15
16 279 MRSA. Furthermore, an increased tendency for people to visit hospital facilities due to
17
18 280 chronic ear infections can also explain the high incidence of ESBL and MRSA, which raises
19
20 281 the danger of exposure to MDR bacteria. Additionally, the tendency to use inanimate objects
21
22 282 to remove earwax can be attributed to the increased proportion of ESBL and MRSA, as these
23
24 283 inanimate objects are often found in environments that may be contaminated with ESBL-
25
26 284 producing bacteria and MRSA (25).

27
28
29
30
31
32 285 Almost all isolated bacteria (93%) were resistant to amoxicillin/clavulanic acid. Nearly three-
33
34 286 quarters of gram-negative bacteria were resistant to ceftazidime, and about half were resistant
35
36 287 to trimethoprim-sulfamethoxazole. On the other hand, 89% of isolate gram-positive were
37
38 288 resistant to erythromycin. ESBL-PE and MRSA isolates were resistant to the most common
39
40 289 antimicrobial agents compared to non-MRSA and non-ESBL-PE. The resistance patterns
41
42 290 found in the current study are similar to those reported in other studies in Tanzania, Kenya,
43
44 291 Ethiopia, India, Egypt, and Romania (3,4,17,18,26–29). The frequent use of these antibiotics
45
46 292 to treat various bacterial infections in our setting and the likelihood that most bacterial
47
48 293 species have developed resistance to antimicrobial drugs over time may contribute to the
49
50 294 observed resistance pattern.

51
52
53
54
55 295 In the present study, most isolated bacteria were sensitive to meropenem and ciprofloxacin.
56
57 296 Ciprofloxacin is a drug of choice for ear infections as per standard treatment guidelines in our
58
59 297 setting. The fact that meropenem is infrequently used to treat ear infections may explain the

1
2
3 298 high sensitivity rate. Surprisingly, we observed that ciprofloxacin is still effective despite
4
5 299 being prescribed often in our setting for treating ear infections. There is no clinical rationale
6
7 300 for why quinolones are still more effective in treating ear infections. However, these results
8
9 301 assure that quinolones are still beneficial as first-line topical antibiotics for ear infections.
10
11
12 302 The present study has some limitations. We were not able to identify the fungi isolates to
13
14 303 species level. This is due to insufficient funding and the availability of resources. To mitigate
15
16 304 this all fungi isolates were stored appropriately for future testing. In addition, due to financial
17
18 305 constraints and lack of equipment, it was impossible to isolate anaerobic bacteria from the
19
20 306 collected pus specimen
21
22

23 307 5. CONCLUSION

24
25
26 308 The results of this study indicate that bacteria are the most common cause of ear infections in
27
28 309 our context. Furthermore, we report that many multidrug-resistant bacteria (ESBL-PE and
29
30 310 MRSA) are implicated in causing ear infections. Therefore, antimicrobial susceptibility
31
32 311 testing is crucial to guide clinicians on appropriately managing ear infections in our setting.
33
34

35
36 312 **Acknowledgements:** The authors wish to acknowledge the Muhimbili National Hospital
37
38 313 (MNH) administration and the Mwanza University, Tanzania, for their support. The authors
39
40 314 are also grateful to all the study participants, the otorhinolaryngology clinic staff, and CPL
41
42 315 staff at MNH.
43
44
45

46
47 316 **Contributors:** AS, DK, and WM contributed to the conceptualization, data collection, and
48
49 317 analysis study. AS, DK, WM, UK, AGM, AM, SM, AMM, MM, SEM, JM, and MM were
50
51 318 involved in manuscript preparation. JM and MM profoundly reviewed the manuscript. AS is
52
53 319 the guarantor of the study. The corresponding author attests that all listed authors meet
54
55 320 authorship criteria and that no one meeting the criteria has been omitted. The lead author (the
56
57 321 manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent
58
59
60

1
2
3 322 account of the study being reported; that no important aspects of the study have been omitted;
4
5 323 and that any discrepancies from the study as planned (and, if relevant, registered) have been
6
7
8 324 explained.

9
10
11 325 **Funding:** No funding was received for this study.

12
13
14 326 **Competing interests:** The authors do not have any conflicts of interest.

15
16
17 327 **Patient consent:** To participate in the present study, written informed consent was obtained
18
19 328 from adult participants (18 years and above). Assent and consent were requested from
20
21 329 adolescents and the parents/ guardians of participants below 18 yrs. The results text, figures,
22
23 330 and tables include no personal participant information.

24
25
26
27 331 **Ethical approval:** Ethical clearance was obtained from Muhimbili University of Health and
28
29 332 Allied Sciences (MUHAS), Senate Research and Publication Committee, with reference
30
31 333 number DA.282/298/01.C/. The MNH administration provided permission to conduct the
32
33 334 study.

34
35
36
37 335 **Availability of data and materials:** All relevant data generated and analyzed during this
38
39 336 study are available from the corresponding author upon reasonable request.

40
41
42 337 **Provenance and peer review:** Not commissioned; externally peer-reviewed.

43 44 45 338 REFERENCES

- 46
47 339 1. Schilder AGM, Chonmaitree T, Cripps AW, Rosenfeld RM, Casselbrant ML, Haggard
48
49 340 MP, et al. Otitis media. *Nat Publ Gr.* 2016;16063(6):1–19.
- 50
51
52 341 2. Atkinson H, Wallis S, Coatesworth AP. Acute otitis media. *Postgrad Med.*
53
54 342 2015;127(4):386–90.
- 55
56
57 343 3. Mushi MF, Mwalutende AE, Gilyoma JM, Chalya PL, Seni J, Mirambo MM, et al.
58
59 344 Predictors of disease complications and treatment outcome among patients with

- 1
2
3 345 chronic suppurative otitis media attending a tertiary hospital , Mwanza Tanzania. BMC
4
5 346 Ear, Nose Throat Disord. 2016;16(1):1–8.
6
7
8 347 4. Mwambete KD, Eulambius M. High Prevalence of Antibiotic-Resistant Otitis Media–
9
10 348 Associated Bacterial Flora of Asymptomatic People Living with HIV at Morogoro
11
12 349 Hospital, Tanzania. J Int Assoc Provid AIDS Care. 2018;17:1–8.
13
14
15
16 350 5. Mushi MF, Buname G, Bader O, Groß U, Mshana SE. Aspergillus fumigatus carrying
17
18 351 TR34 / L98H resistance allele causing complicated suppurative otitis media in
19
20 352 Tanzania : Call for improved diagnosis of fungi in sub-Saharan Africa. BMC Infect
21
22 353 Dis. 2016;16(464):16–21.
23
24
25
26 354 6. Minja BM, Machemba A. Prevalence of otitis media, hearing impairment and cerumen
27
28 355 impaction among school children in rural and urban Dar es Salaam, Tanzania. Int J
29
30 356 Pediatr Otorhinolaryngol. 1996;37(1):29–34.
31
32
33 357 7. Sinha A, Mohapatra LN. Otomycosis - A clinical and mycological study. Indian J
34
35 358 Otolaryngol. 1961;13(3):128–37.
36
37
38
39 359 8. Vaidya K, Madhup SK, Shrestha BL, Gautam A, Tuladha NR. Bacteriological and
40
41 360 Mycological profile of Chronic Suppurative Otitis Media among patients visiting
42
43 361 Dhulikhel Hospital. Ann Clin Chem Lab Med. 2015;1(1):37–41.
44
45
46 362 9. Martin TJ, Kerschner JE, Flanary VA. Fungal causes of otitis externa and
47
48 363 tympanostomy tube otorrhea. Int J Pediatr Otorhinolaryngol. 2005;69(11):1503–8.
49
50
51 364 10. Kumar A. Fungal spectrum in otomycosis patients. JK Sci. 2005;7(3):152–5.
52
53
54 365 11. Hall JW, Bouchard J, Bookstaver PB, Haldeman MS, Kishimbo P, Mbwanji G, et al.
55
56 366 The Mbeya Antimicrobial Stewardship Team: Implementing Antimicrobial
57
58 367 Stewardship at a Zonal-Level Hospital in Southern Tanzania. Pharmacy.

- 1
2
3 368 2020;8(2):107.
4
5
6 369 12. Seni J, Mapunjo SG, Wittenauer R, Valimba R, Stergachis A, Werth BJ, et al.
7
8 370 Antimicrobial use across six referral hospitals in Tanzania: A point prevalence survey.
9
10 371 BMJ Open. 2020;10(12):1–9.
11
12
13 372 13. NPS Medicinewise. Antibiotic resistance Antibiotic resistance. Prev Control [Internet].
14
15 373 2010;(July):2005–6. Available from:
16
17 374 [http://www.nps.org.au/__data/assets/pdf_file/0009/318879/NPSMW-antibiotic-](http://www.nps.org.au/__data/assets/pdf_file/0009/318879/NPSMW-antibiotic-resistance-the-facts.pdf)
18
19 375 [resistance-the-facts.pdf](http://www.nps.org.au/__data/assets/pdf_file/0009/318879/NPSMW-antibiotic-resistance-the-facts.pdf)
20
21
22
23 376 14. Testing S. M100 Performance Standards for Antimicrobial.
24
25
26 377 15. Abraham ZS, Ntunaguzi D, Kahinga AA, Mapondella KB, Massawe ER, Nkuwi EJ, et
27
28 378 al. Prevalence and etiological agents for chronic suppurative otitis media in a tertiary
29
30 379 hospital in Tanzania. BMC Res Notes. 2019;12(429):1–6.
31
32
33
34 380 16. Pavani K, Krishnamurthy S, Swetha KS, Supriya PS. Chronic Suppurative Otitis
35
36 381 Media (CSOM): Evaluation of fungal and aerobic bacterial agents and antibiotic
37
38 382 sensitivity pattern of the bacterial isolates. Int J Med Microbiol Trop Dis.
39
40 383 2020;5(4):214–7.
41
42
43
44 384 17. Aduda DSO, Macharia IM, Mugwe P, Oburra H, Farragher B, Brabin B, et al.
45
46 385 Bacteriology of chronic suppurative otitis media (CSOM) in children in Garissa
47
48 386 district, Kenya: A point prevalence study. Int J Pediatr Otorhinolaryngol.
49
50 387 2013;77(7):1107–11.
51
52
53
54 388 18. Kumar D, Agrawal A, Kumar S, Gupta N. “ A Study of the Microbiological Profile of
55
56 389 CSOM in A Tertiary Care Centre of North India .” J Dent Med Sci. 2019;18(5):20–4.
57
58
59 390 19. Uddén F, Filipe M, Reimer Å, Paul M, Matuschek E, Thegerström J, et al. Aerobic
60

- 1
2
3 391 bacteria associated with chronic suppurative otitis media in Angola. *Infect Dis*
4
5 392 Poverty. 2018;7(1):1–10.
6
7
8 393 20. Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: Aetiology, clinical features
9
10 394 and therapy. *Mycoses*. 2012;55(5):404–9.
11
12
13 395 21. Kiakojuri K, Armaki MT, Rajabnia R, Pournajaf A, Karami M, Khademian A, et al.
14 396 Outer ear infections in Iran: A review. *Open Access Maced J Med Sci*.
15
16 397 2019;7(7):1233–40.
17
18
19 398 22. Zlatian O. Etiology and pathogenesis of chronic suppurative otitis media. *Bluestone*
20
21 399 *kena*. 2007;13(1):16–7.
22
23
24 400 23. Viswanatha B, Naseeruddin K. Fungal infections of the ear in immunocompromised
25
26 401 host: A review. *Mediterr J Hematol Infect Dis*. 2011;3(1):1–4.
27
28
29 402 24. Shuaib Kayode A, Kayode Rashaq A, Tayo I, Viswanatha B, Naseeruddin K. A
30
31 403 Prospective Analysis of Otomycosis in a Tertiary Care Hospital. *Int J Trop Dis*.
32
33 404 2020;3(1):1–8.
34
35
36 405 25. Endaylalu K, Abera B, Mulu W. Extended spectrum beta lactamase producing bacteria
37
38 406 among outpatients with ear infection at FelegeHiwot Referral Hospital, North West
39
40 407 Ethiopia. *PLoS One* [Internet]. 2020;15(9 September):1–14. Available from:
41
42 408 <http://dx.doi.org/10.1371/journal.pone.0238891>
43
44
45
46 409 26. Allam AAE, Tantawy AEE, Mohamed KAE, El ghamrey NAM, Morad EA, El Shafei
47
48 410 MAE. Short Communication: Otitis externa in a tertiary care hospital in Zagazig,
49
50 411 Egypt: Isolated pathogens and their antibiotic sensitivity patterns. *African J Clin Exp*
51
52 412 *Microbiol*. 2019;21(1):60.
53
54
55
56 413 27. Argaw-Denboba A, Abejew AA, Mekonnen AG. Antibiotic-resistant bacteria are
57
58
59
60

- 1
2
3 414 major threats of otitis media in wollo area, northeastern Ethiopia: A ten-year
4
5 415 retrospective analysis. *Int J Microbiol.* 2016;2016(8724671):1–9.
6
7
8 416 28. Anghelina F, Zlatian O, Ciolofan MS, Calina D, Docea AO, Hainarosie R, et al.
9
10 417 Bacteriological profiles and antibiotic susceptibility patterns in complicated bacterial
11
12 418 infections of the ears, nose and throat. *Rev Chim.* 2019;70(12):4426–31.
13
14
15
16 419 29. Seid A, Deribe F, Ali K, Kibru G. Bacterial otitis media in all age group of patients
17
18 420 seen at Dessie referral hospital, North East Ethiopia. *Egypt J Ear, Nose, Throat Allied*
19
20 421 *Sci.* 2013;14(2):73–8.
21
22
23
24 422


1
2
3 424 **Figure legends**
4
5

6 425 **Figure 1: Types of ear infection among study participants at MNH**
7

8 426 The figure illustrates the distribution of ear infections among patients presenting with signs
9 and symptoms of ear infection attending the otorhinolaryngology clinic at MNH (N=255).
10 427
11 428 OM, OE, and CSOM stand for otitis media, otitis externa, and chronic suppurative otitis
12 media, respectively.
13 429
14
15
16
17


18 430 **Figure 2A-C: Distribution of bacterial isolates**
19

20
21 431 The figure depicts the distribution of bacteria spp isolated among patients with ear infections
22 attending the otorhinolaryngology clinic at MNH (n=131)(A). According to the type of ear
23 432 infection (n=131), where OM (otitis media), OE(otitis externa), and CSOM (chronic
24 433 suppurative otitis media) (B). Distribution of ESBL-producing bacteria among isolated gram-
25 434 negative bacteria in patients attending the otorhinolaryngology clinic at MNH (n = 61) (C).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41


A



B



C



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

STROBE Statement

	Page Number	Description
Title and abstract	1-3	<p>(a) Etiology of ear infection and antimicrobial susceptibility pattern among patients attending otorhinolaryngology clinic at a tertiary hospital in Dar es Salaam, Tanzania (hospital-based cross-sectional study)</p> <hr/> <p>(b) OBJECTIVES: To determine the etiological pathogens causing ear infections and their antimicrobial susceptibility patterns among patients with ear complaints at a tertiary hospital in Dar es Salaam.</p> <p>DESIGN: Hospital-based cross-sectional study.</p> <p>SETTINGS: Otorhinolaryngology clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania.</p> <p>PARTICIPANTS: Patients presenting with signs and symptoms of ear infection.</p> <p>MAIN OUTCOME MEASURE: Bacteria and fungi isolated from ear swab specimens of patients presenting with signs and symptoms of ear infection; and antimicrobial susceptibility patterns of isolated bacteria.</p> <p>RESULTS: Two hundred fifty-five participants were enrolled, with a median age of 31 years and an interquartile range of 15- 49. Otitis externa was the predominant type of ear infection, accounting for 45.1%. We observed positive bacteria culture in 53.3% of study participants, in which 41% of isolates were obtained from patients with chronic suppurative otitis media (CSOM). Moreover, <i>S. aureus</i> (27.3%) and <i>P. aeruginosa</i> (24.2%) were the most frequently isolated bacteria, while <i>Candida spp</i>, 12(63.8%), and <i>Aspergillus spp</i>, 9(36.2%) were the only isolated fungi. We report that 93% of isolated Enterobacterales were resistant to amoxicillin /clavulanic acid, and 73% were resistant to ceftazidime. In addition, we detected 34.4% extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE) and 44.4% methicillin-resistance Staphylococcus aureus (MRSA). We also detected resistance to ciprofloxacin a primary topical antibiotic used in management of ear infection is 22%.</p> <p>CONCLUSIONS: The findings from this study reveal that the leading etiological agent of ear infection is bacteria. Furthermore, our findings show a significant proportion of ESBL-PE and MRSA-causing ear infections. Hence, detecting multidrug-resistant bacteria is crucial to improving ear infection management.</p>
<hr/>		
Introduction		
Background/rationale	4-5	<p>An ear infection is among the leading cause of deafness in many developing countries. Unfortunately, most patients with ear infections in resource-limited settings delay seeking medical attention; hence, usually present with complications. Bacteria are the leading pathogens of ear infection whereby, <i>Staphylococcus aureus</i>, <i>Pseudomonas aeruginosa</i>, <i>Proteus mirabilis</i>, and <i>Klebsiella species</i> are the dominant bacteria species causing ear infection globally. In addition, <i>Candida spp</i> and <i>Aspergillus spp</i> are predominant fungal isolates</p>

responsible for ear infections. However, fungal ear infections are often undiagnosed due to limited diagnostic opportunities, especially in resource-limited countries, including Tanzania.

Most practitioners in our settings tend to treat ear infections empirically or adhere to the Standard Treatment Guideline (STG) without considering laboratory investigation and Antimicrobial susceptibility testing (AST) results. This has created a gap in managing most ear infections, which raises the risk of acquiring multidrug-resistant bacteria. When first-line antibiotics cannot treat infections, more costly antibiotics must be utilized. This consequently affects patients' treatment options, resulting in prolonged hospital stays and increased healthcare costs, which impacts families' financial burden and quality of life.

Etiological studies of ear infections are important to guide the choice of an effective antibiotic and monitoring bacterial patterns and their varying antimicrobial susceptibilities. This is crucial for risk analysis, mitigation measures, and logistical plans. Therefore, the present study aimed to determine the etiological pathogens and antimicrobial susceptibility patterns of bacteria causing ear infections. The data obtained will be used to strengthen the prevention and control measures and to update the management and treatment options for ear infections. Also, the information will serve as a baseline for countrywide surveillance of antibiotic resistance.

Objectives	4	1. To determine bacterial species and proportion of fungi causing ear infection among patients attending otorhinolaryngology clinic at MNH. 2. To determine the antimicrobial susceptibility patterns of bacteria isolates causing ear infection among patients attending otorhinolaryngology clinic at MNH
Methods		
Study design	5	This is a hospital-based cross-sectional study
Setting	5	The study was carried out at the Muhimbili National Hospital (MNH), in Dar es Salaam, Tanzania, in the otorhinolaryngology clinic from March to July 2021. A standardized questionnaire and patient's medical records were used to obtain participant's social demographic, behavioural and clinical information. Ear swab was collected, then culture and antimicrobial susceptibility testing was performed for the isolated bacteria species.
Participants	5	The study included all the patients attending otorhinolaryngology clinic at MNH with ear complaints such as accumulation of fluid in the middle ear, bulging of the eardrum, ear pain, ear itching, perforation of the eardrum and ear discharge (otorrhea) and participants who consented or assented to participate in the study. We excluded patients with other hearing disorders (congenital malformations, physical head injury, etc.). And Patients who are on regular check-ups
Variables	6	Outcome variables -Ear infection Independent variables - demographic data (age, sex, marital status, occupation, and education) and behavioural risk characteristics (swimming, frequent use of earphones, cotton buds, sharp objects, and cigarette smoking). Clinical information, including the type of ear infection, use of antibiotics, nasal congestion or blockage, recurrent upper respiratory tract infection (URTI), and cerumen impaction
Data sources/	6	Outcome variables – Laboratory (Culture and sensitivity) was the source of data

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

measurement		for outcome variables, where by percentage was used to summarize the bacteria and fungi species isolates and the magnitude of resistance for each isolated bacteria.
Bias	8	<p>Efforts to address potential sources of Bias</p> <p>Results from this study depended on good practice in the pre-analytic stage including correct procedures during sample collection, proper labelling of the specimen and safe transportation of the sample including proper storage and temperature (2°C– 8°C) to the laboratory and this was guided by standard operating procedures. Clinical and demographic data for each study participant was obtained by using a standardized questionnaire and patients’ medical records. The use of a standard questionnaire is said to be reliable because all participants were subjected to the same questionnaire when evaluating the factors associated with ear infection.</p>
Study size	5	<p>The sample size was estimated by using the Kish Leslie formula (1965) using the prevalence of 62% obtained from a study done in Tanzania.</p> $N = \frac{Z^2 P (1-P)}{D^2}$ <p>Whereby Z=standard deviation of the normal distribution = 1.96 (confidence level at 95%) P=prevalence 62.1% (5) D=Margin of error 6% N=251 The minimum required sample size was 251 participants with ear infections.</p>
Quantitative variables	8	Quantitative variables were summarized by calculating measures such as mean, median standard deviation, and quartiles to summarize the central tendency and dispersion of the data
Results		
Descriptive data	9-10	<p>(a) Two hundred fifty-five participants were recruited; 52.5% (134/255) were males. The median age was 31 years (IQR: 15- 49). The majority (30.2%) of participants were students, 32.9% had a college education, and 15.7% were from outside Dar es Salaam region (Table 1). The median duration of ear infections was 210 days (IQR: 21-1095). Otitis externa (OE) was the most common type of ear infection, accounting for 45.1% (115/255), followed by Chronic Suppurative Otitis Media (CSOM) (41.2%). Around 49% of the participants with ear infections had a history of antibiotic use, whereby ciprofloxacin ear drop was the most prescribed topical antibiotic. Additionally, 33.3% of the study participants had nasal congestion/blockage/discharge, and 28.2% had recurrent URTI</p> <p>(b) No participant with missing variable</p>
Outcome data	10-12	<p>In this study, 136 out of 255 (53.3%) participants had a positive aerobic culture for either bacterial or fungal pathogen. A total of 150 isolates (bacteria and fungi) were identified, of which 87.3% (131/150) were bacteria. Of the isolated bacteria, Gram-negative, 71.0% (93/131) were predominant.</p> <p>The predominant bacterial isolates were <i>S. aureus</i>, 27.5% (36/131), followed by <i>Pseudomonas aeruginosa</i>, 24.4% (32/131). On the other hand, <i>Candida spp</i> accounted for 63.2% (12/19) of the isolated fungi (data not shown). Further stratification of isolated pathogens by type of ear infection showed that <i>S. aureus</i> 16/131 (12.2%) was the most prevalent bacterium in OE patients, whereas <i>P.</i></p>

aeruginosa 22/131 (16.8%) predominated in CSOM patients. In the present study 34.4% (21/61) of the *Enterobacteriales*, excluding *Pseudomonas aeruginosa*, were extended-spectrum beta-lactamase producing *Enterobacteriales* (ESBL-PE); and *Klebsiella spp* was predominant, accounting for 33.3% (7/21) of the ESBL-PE isolates. On the other hand, 44.4% (16/36) of the *S.aureus* species were MRSA.

Almost all (93%) isolated Enterobacteriales were resistant to amoxicillin/clavulanic acid, more so *E. coli* and *Acinetobacter spp* were 100% resistant. Also, 73% of isolated bacteria were resistant to ceftazidime, whereby *Pseudomonas aeruginosa* had the highest resistance rate of 75%. In addition, 43% of isolated bacteria were resistant to trimethoprim-sulfamethoxazole, whereby *E.coli* was leading with a 75% resistance rate.

Discussion

Key results

53.3% of research participants reported positive bacteria cultures. *S. aureus* (27.3%) and *P.aeruginosa* (24.2%) were the most frequently isolated bacteria, whereas *Candida spp.* 12(63.8%), and *Aspergillus spp.* 9(36.2%) were the only isolated fungi. 73% of the identified Enterobacteriales were resistant to ceftazidime, while 93% were resistant to amoxicillin/clavulanic acid. Furthermore, we identified 44.4% methicillin-resistant *Staphylococcus aureus* (MRSA) and 34.4% extended-spectrum beta-lactamase-producing Enterobacteriales (ESBL-PE)

Limitations

14-15

1. The present study was not able to identify the fungi isolates to species level. This is due to insufficient funding and availability of resources. To mitigate this all fungi isolates were stored appropriately for future testing to specie level.
2. Due to financial constraints and lack of equipment, it was also not possible to isolate anaerobic bacteria from the collected pus specimen

Interpretation

12-14

According to the study many ear infections are of bacterial etiology, *S. aureus* and *Pseudomonas aeruginosa* are the most commonly isolated bacteria. The majority of isolated bacteria were resistant to amoxicillin/clavulanic acid, sulfamethoxazole-trimethoprim, Erythromycin and third-generation cephalosporins. The most effective antibiotics were ciprofloxacin and meropenem. The findings suggest that ear infection management procedures and the choice of an effective antibiotic need to be reviewed. The results are consistent with research conducted in Tanzania by Kennedy M. et al. (2019) in Morogoro, Zephania A. et al. (2019) in Dar es Salaam, Martha M. et al. (2016) in Mwanza, as well as research from Kenya and India.

The current study revealed a high proportion of MRSA (44.4%) and ESBL-PE (34.4%). ESBL-PE and MRSA isolates were resistant to the most common antimicrobial agents compared to non-MRSA and non-ESBL-PE. In addition, our study showed *Klebsiella spp* (33.3%) as the dominant ESBL-PE. The higher proportion of MRSA and ESBL-PE coincide with other studies in Tanzania, Kenya, Ethiopia, India, Egypt, and Romania. The greater inclination for self- and empirically prescribing antibiotics without considering laboratory culture and sensitivity may explain the higher proportion of ESBL and MRSA. The high incidence of ESBL and MRSA can also be explained by an increased inclination for people to visit hospital facilities due to chronic ear infection, which raises the danger of exposure to MDR bacteria. Additionally, the tendency to use inanimate

objects to remove earwax can be attributed to the increased proportion of ESBL and MRSA, as these inanimate objects are often found in environments that may be contaminated with ESBL-producing bacteria and/or MRSA

Ciprofloxacin is a drug of choice for ear infections as per standard treatment guidelines in our setting. The fact that meropenem is infrequently used to treat ear infections may explain the high sensitivity rate. Surprisingly, we observed that ciprofloxacin is still effective despite being prescribed often in our setting for treating ear infections. There is no clinical rationale as to why quinolones are still more effective in treating ear infections, but these results assure that quinolones are still beneficial as first-line topical antibiotics for ear infections.

Generalisability	According to the study's findings, bacteria are the most common etiological factor in ear infections. Additionally, our results indicate that a significant percentage of ear infections are caused by ESBL-PE and MRSA. Therefore, identifying multidrug-resistant bacteria is essential to enhancing the management of ear infections. The study has also identified patterns of antimicrobial susceptibility that are helpful in guiding the selection of empirical treatment in environments with limited resources and comparable geographic, demographic, and social characteristics.
Other information	
Funding	15 No funding was received for this study.